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Abstract
Background: Short bowel syndrome (SBS) is defined as the malabsorptive state that often follows massive
resection of the small intestine. Most cases originate in the newborn period and result from congenital anomalies.
It is associated with a high morbidity, is potentially lethal and often requires months, sometimes years, in the
hospital and home on total parenteral nutrition (TPN). Long-term survival without parenteral nutrition depends
upon establishing enteral nutrition and the process of intestinal adaptation through which the remaining small
bowel gradually increases its absorptive capacity. The purpose of this article is to perform a descriptive systematic
review of the published articles on the effects of TPN on the intestinal immune system investigating whether long-
term TPN induces bacterial translocation, decreases secretory immunoglobulin A (S-IgA), impairs intestinal
immunity, and changes mucosal architecture in children with SBS.
Methods: The databases of OVID, such as MEDLINE and CINAHL, Cochran Library, and Evidence-Based
Medicine were searched for articles published from 1990 to 2001. Search terms were total parenteral nutrition,
children, bacterial translocation, small bowel syndrome, short gut syndrome, intestinal immunity, gut permeability,
sepsis, hyperglycemia, immunonutrition, glutamine, enteral tube feeding, and systematic reviews. The goal was to
include all clinical studies conducted in children directly addressing the effects of TPN on gut immunity.
Results: A total of 13 studies were identified. These 13 studies included a total of 414 infants and children
between the ages approximately 4 months to 17 years old, and 16 healthy adults as controls; and they varied in
design and were conducted in several disciplines. The results were integrated into common themes. Five themes
were identified: 1) sepsis, 2) impaired immune functions: In vitro studies, 3) mortality, 4) villous atrophy, 5)
duration of dependency on TPN after bowel resection.
Conclusion:  Based on this exhaustive literature review, there is no direct evidence suggesting that TPN
promotes bacterial overgrowth, impairs neutrophil functions, inhibits blood's bactericidal effect, causes villous
atrophy, or causes to death in human model.
The hypothesis relating negative effects of TPN on gut immunity remains attractive, but unproven. Enteral 
nutrition is cheaper, but no safer than TPN. Based on the current evidence, TPN seems to be safe and a life saving 
solution.
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Background
In the late 1960's, the introduction of total parenteral
nutrition (TPN) as an alternative nutrition provided a life
saving solution to children with chronic bowel obstruc-
tions, fistulas, loss of mucosal body surfaces, short bowel
syndrome, and other clinical problems that precluded
enteral diet by mouth or tube feeding for long periods of
time. Intravenous administration of TPN became an
essential fluid to meet nutritional needs and to avoid pro-
gressive starvation-induced malnutrition, which changed
the outcome of patients from dying [1]. Since then, TPN
has been a gold standard practice in treatment and a pan-
acea for infants and children who are unable to eat or to
absorb enterally provided nutrients [1-4]. As a result, the
prognosis for patients with SBS has changed dramatically
and the management with the expected survival for
infants with congenital gastrointestinal anomalies and gut
failure have improved significantly [5,6].
However, its use has been shown to associate with an
increased incidence of infection [7]. A number of inde-
pendent experimental studies have been carried out
shown that intravenous TPN negatively influences gut
barrier functions and mucosal immunity while withhold-
ing nutrients by mouth or enteral tube feeding, after the
resection of small intestine. These studies demonstrated
that TPN is associated with: 1) increases in intestinal per-
meability, bacterial overgrowth, and bacterial transloca-
tion, 2) rapid changes in gut-associated lymphoid tissue
(GALT) T cells, B cell, and secretory immunoglobulin A
(S-IgA) levels, 3) impairment in IgA-mediated mucosal
immunity defenses in the respiratory tract, 4) impairment
in neutrophil function, 5) alteration in gastrointestinal
(GI) architecture or mucosal atrophy [8-14].
This paper presents a descriptive systematic review of pub-
lished research articles on the effects of the long-term TPN
on gut mucosal immunity in children with SBS; specifi-
cally, it addresses whether TPN: 1) promotes bacterial
translocation, 2) impairs intestinal mucosal immunity by
decreasing S-IgA levels, 3) inhibits neutrophil and
cytokine functions in blood, 4) promotes atrophy of the
mucosal villi, 5) hyperglycemia, and 6) causes death. It is
hoped that these findings will expand the knowledge of
pediatric nurses, and have an impact on clinical practice
by being included in the pediatric parenteral nutritional
guidelines. Since the review of literature did not reveal any
systematic reviews of TPN and mucosal immunity on chil-
dren with SBS, the aim of this descriptive systematic
review of individually published scientific studies is to
impart a better understanding of the effects of TPN on gut
mucosal defense and barrier function.
Short bowel syndrome, one of the major indications for
diagnostic categories using long-term TPN [15], is a clini-
cally complex disorder resulting from multiple alterations
of normal intestinal anatomy and physiology and produc-
ing a variety of nutritional, infectious, and metabolic
complications because of impairment caused by vascular
disease, intestinal volvulus, ischemic bowel, inflamma-
tory bowel, and necrotizing enterocolitis (NEC) [16,17].
SBS is also described as, " the malabsorptive state" that
mostly follows massive resection of the small intestine
[18,19].
After resection, the residual or remaining small bowel
undergoes intestinal adaptation, a process characterized
by mucosal hyperplasia, villus lengthening, increased
crypt depth (intestinal gland), and bowel dilation. The
process of adaptation is complex and includes both struc-
tural and functional changes. The earliest sign can be
detected within 24-48 hours, and process may continue
for months, possibly years. In the early phase, mucosal
hyperplasia and villus hypertrophy occur. Oral nutrients
and hormones stimulate this intestinal adaptation. The
main clinical challenge in SBS lies in managing the many
nutritional problems that occur as a result of malabsorp-
tion secondary to the reduced absorptive surface area
[20,21].
Anatomy and physiology of the gastrointestinal immune 
system
The normal length of intestine in full-term newborn is
estimated at 200 cm-250 cm [22], and the normal adult
small intestine is about 400 cm [23]. The small intestine
extends from the pylorus to the ileocecal valve. It is func-
tionally divided into three segments: the duodenum, the
jejunum, and the ileum. The duodenum begins at the
pylorus and ends where it joins the jejunum. The end of
jejunum and beginning of the ileum are not distinguished
by an anatomic marker[24]. The ileocecal valve functions
as a barrier to prevent both reflux of colonic contents into
small intestine and rapid passage of contents through the
ileum [25].
The primary function of the small intestine is to absorb
nutrients into the circulation [26]. During the course of
this activity the intestine is exposed to a wide variety of
antigens derived from foods, resident bacteria, and invad-
ing microorganisms. All products of carbohydrate, pro-
tein, and fat digestion, as well as most of the ingested
electrolytes, vitamins, and water are normally absorbed by
small intestine indiscriminately. Normally, nutrient
digestion and absorption occur predominantly in the
upper intestine. The jejunum has a larger absorptive sur-
face due to longer villi, and a higher concentration of
mucosal digestive enzymes and transport proteins,
whereas the ileum has shorter villi. Very little absorption
occurs in the ileum, not because the ileum does not have
absorptive capacity but because most absorption has beenBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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already accomplished before the intestinal contents reach
the ileum[21,25,27].
The tight junctions of the jejunum are highly porous, so
that exposure of the mucosa to hyperosmolar nutrient
solutions leads to efflux or flow of water and electrolytes
into the lumen (interior space of intestine). This fluid is
then reabsorbed in both the ileum and colon. The distal
ileum has specialized transport carriers for the absorption
of bile salts and vitamin B12. The ileocecal valve forms an
important barrier, slowing transit from the small intestine
to the colon and limiting bacterial colonization of the
small intestine [21]. Ileocecal valve prevents retrograde
colonization of distal small bowel to a significant extent.
In the absence of the valve, however, free reflux of right-
sided liquid colonic content occurs, and the total load of
colonic bacteria exposed to the distal intestine increases
greatly [28].
Histological organization of the intestinal wall is divided
into four major layers. These major layers include: (1) the
mucosa, the innermost layer, which comprises epithelium,
lamina propria, and muscularis layers; (2) The submucosa
consists largely of loose connective tissue with collagen
and elastin fibrils. Glands, nerve trunks and blood vessels
are also present in the submucosa; (3) The next layer, the
muscularis, typically consists of two substantial layers of
smooth muscle cells; an inner circular layer and an outer
longitudinal layer; and (4) The serosa  is the outermost
layer of intestinal tract [25,29-31].
The mucosa is considered an "architectural marvel." The
epithelial layer of mucosa regulates absorptive, secretory,
and protective barrier functions. This thin epithelial layer
composed of columnar absorptive cells, goblet cells,
undifferentiated crypt epithelial cells, panet cells, ente-
roendocrine cells, tuft cells, cup cells, and intraepithelial
lymphocytes [32]. This mucosal layer covers the villus, a
finger like projection that is made up of epithelial cells
called enterocytes and its crypt or submucosal gland, and
is responsible for absorption of electrolytes, water, and
nutrition. The enterocyte surface contains special luminal
projections called microvilli, which provide an increased
surface area that is referred to as brush border membrane.
Although not part of the epithelium, mucus on the surface
of the mucosa shields the mucosal epithelial cells from
direct contact with the intestinal luminal environment
[29,32,33].
Beneath the mucosal epithelium is the connective and
supportive tissue called the lamina propria. The lamina
propria contains various immunocompetent cells, includ-
ing plasma cells, mast cells, macrophages, and lym-
phocytes that produce not only immunoglobulins but
also cytokine mediators [32].
Mucosal defense system
Nonimmune antibacterial factors
A complex intestinal mucosal defense system plays an
important role to prevent invasion of gut bacteria or
absorption of endotoxin. Peristaltic waves and contrac-
tions sweep the intestinal contents in a steady distal flow
toward the colon, which is a major importance in reduc-
ing the growth of bacteria in the proximal intestine [28].
During fasting, motilin, a putative regulatory peptide, is
believed to be one mechanism that initiates the cyclic
motility pattern termed the migrating motor complex
(MMC), which functions as a gastrointestinal "house-
keeper" by sweeping lumenal content and bacteria from
stomach and small bowel into colon[34].
Mucus, an epithelial secretion, also helps reducing bacte-
rial overgrowth. Mucus has special properties that enable
to trap bacteria in an intraluminal location while moving
organisms distally in bolus fashion. Carbohydrate serves
as a nutrient for some bacteria, thus attracting them to a
mobile colonization site that is continuously replaced.
Enzymatic digestion also significantly reduces bacterial
overgrowth. Pancreatic juice has antibacterial activity.
Intestinal secretions from the stomach, intestine, and pan-
creas are a significant deterrent to growth due to their abil-
ity to dilute the bacterial mass [28,32].
Gastric acidity acts as an initial line of defense against
ingested bacteria. Gastric juice with pH less than 4.0 is
bactericidal for most organisms, although not immedi-
ately [28]. In one in vitro study, bacteria instilled into an
intact lumen of a normal human stomach were promptly
killed in less than 15 minutes at a pH of less than 3.0, but
remained viable in the achlorhydric stomach for at least 1
hour [35]. Chronic inhibition of gastric acid secretion by
histamine2 (H2) receptor blockade in healthy adults, how-
ever, has been shown to increase the number of gastric
bacteria [36].
The intestinal tight junctions between epithelial cells and
permeability have been reviewed [37]. Permeability refers
to the ability of small molecules to penetrate the gastroin-
testinal mucosa. The tight junctions are an important part
of the intestinal barrier. Tight junctions are dynamic struc-
tures, and their barrier function may be modulated by
nutrients such as glucose and amino acids as well as bac-
terial toxins and chemotaxins. Loss of intestinal barrier is
associated with translocation of enteric bacteria in animal
modal, but in humans bacterial translocation is not asso-
ciated with increased intestinal permeability or villous
atrophy. Glutamine, a nonessential amino acid, is consid-
ered to be the principal respiratory fuel for enterocytes. A
lack of glutamine promotes mucosal atrophy and
increases intestinal permeability [37-39].BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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Thomson and colleagues [40-42], citing various sources,
suggest that enterocytes function as "nonclassical"
immune cells, which play a major role as a source of
proinflammatory cytokines and cytotoxins. A key proin-
flammatory mediator produced in intestinal mucosa is
the free radical nitric oxide. Nitric oxide (NO), a pluripo-
tent signaling and effector molecule, is increased with
mild acidosis and enhances intestinal permeability. Nitric
oxide is produced as a result of conversion of arginine to
citrulline by the enzyme NO synthase (NOS). Nitric oxide
has potent bactericidal effects against a wide variety of
micro-organisms, including the majority of the intestinal
microflora. Furthermore, arginine supplementation has
been shown to improve survival in a guinea-pig model of
peritonitis. Inhibition of NO synthesis has been shown to
increase intestinal permeability via mast cells, which sug-
gests that NO may regulate intestinal barrier function
[43,44].
The permeability of the intestine can be increased by vari-
ety of factors, such as psychological stress, fasting, and cer-
tain drugs. During fasting or malnutrition, intestinal
secretion of ions and fluid increased, permeability to ions
and macromolecules is increased and associated mucosal
atrophy reduces intestinal absorption of nutrients. Some
drugs also alter intestinal permeability. Nonsteroidal anti-
inflammatory drugs (NSAIDs) increase intestinal permea-
bility in both animals and humans. Glutamine, the major
source of the small intestinal mucosa, may be partially
normalize this NSAID-induced permeability [37,45].
Immunological factors
The gastrointestinal track or gut associated lymphoid tis-
sue (GALT) has an important role in gut immunity. The
gut is considered the largest lymphoid organ in the body
housing more than 1012 lymhocytes and more antibody
(secretory IgA) than any other site in the body including
spleen [46]. The lamina propria plasma cells produce
secretory immunoglobulin A (S-IgA) in response to food
antigens and microorganisms. Secretory IgA coats the
lumen or interior surface of small intestine and prevents
any microbial pathogens or viruses penetrating the epithe-
lial layer and passing into the other organs [29,47].
S-IgA contains antibodies directed to biologically active
antigens such as viruses, bacteria, enterotoxins, and
enzymes normally restricted to the intestinal tract. A
reduction in S-IgA level results in a greater frequency of GI
infections and impaired reticuloendothelial or macro-
phage function, which predispose the child to systemic
bacteremia [12,46,48].
The effects of surgery or trauma on mucosal immunity
After surgical intervention, sympathetic response is acti-
vated creating a positive relationship between the severity
of injury and the plasma concentration of adrenalin,
noradrenalin and dopamine [49]. Following injury, the
inflammatory cytokines, such as tumor necrosis factor
(TNF), interleukin-1 (IL-1) and interleukin-6 (IL-6) are
also released, which act only locally [39]. Cytokines are
hormonelike peptides or intracellular signaling proteins
released from white blood cells and all nucleated cells.
They function by serving as chemical messengers within
the immune system, and also communicate with certain
cells in the nervous system. They have immune modulat-
ing effects, in which they work in parallel with other signal
arising from direct cell-to-cell contact, providing a com-
munication network involved in everyday function of the
immune response [50-52].
In the systemic level, counter-regulatory hormones, such
as adrenocorticotropic hormone (ACTH), antidiuretic
hormone (ADH), catecholamines and stress hormone,
cortisol are released. These cytokines and systemic hor-
mones working together cause the multiorgan system fail-
ure. They also induce hypercatabolism, which is
characterized by protein breakdown within skeletal mus-
cle, accelerated breakdown of branched-chain amino
acids and increased release of glutamine and alanine into
systemic amino-acid pool. Glutamine, conditionally
essential amino acid, is critical as an energy source for
enterocytes, immune cells, and rapidly growing tissues.
Overall, physiological stress response results with
increased intestinal permeability and bacterial transloca-
tion, which promotes sepsis or multiorgan failure and
potantiate hypercatabolism and protein-calorie malnutri-
tion [39].
During illness, stress increases the concentration of coun-
terregulatory hormones (glucagons, epinephrine, cortisol,
and growth hormone) and cytokines. Counterregulatory
hormones increase serum blood sugars by increasing
hepatic glucose production and by decreasing peripheral
glucose uptake [53]. Glucose turnover is increased in sep-
sis and trauma, but glucose is oxidized with reduced effi-
ciency. Fat becomes a preferred energy substrates in septic
patients. In critical surgical illness the rates of both protein
synthesis and catabolism are increased. However, the
increase in catabolism is of greater magnitude resulting in
a net breakdown of protein and, if prolonged, immune
compromise [49]. Overall, this leads to prominent meta-
bolic derangements composed of high release and low use
of glucose, amino acids, and free fatty acids (FFA), result-
ing in increased blood levels of these substrates. Increased
levels of glucose and FFA have stimulating effects on
inflammatory signaling leading to additional release of
proinflammatory mediators and endothelial and neu-
trophil dysfunction. Insulin has the inherent capability to
counteract the metabolic changes in septic patients [54].BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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Complications of SBS
The most important ongoing complications in children
with SBS reported in the literature are: recurrent sepsis,
catheter related sepsis, TPN-associated cholestasis, meta-
bolic disturbances, hyperglycemia, electrolyte imbal-
ances, hypertriglyceridemia, gastric hypersecretion,
diarrhea, and organ dysfunction [15,55-57].
Bacterial overgrowth
Bacterial overgrowth is defined as the presence of poten-
tially pathogenic microorganism (PPM) in high concen-
tration (≥ 105 colony forming units/mL) [58]; that is,
increased numbers and species of bacteria in the small
intestine. Bacterial growth in the normal bowel is control-
led by gastric acid, pancreatic enzyme activity, enterocyte
turnover, normal peristaltic activity in the small intestine,
and ileocecal valve [59]. Bacterial overgrowth is found in
children who have no ileacecal valve, the primary means
for preventing reflux of bacteria from the colon into the
small intestine. Progressive dilation of the small intestine
as part of the adaptation response limits the efficacy of
peristalsis in ridding the small intestine of bacteria. The
diagnosis of bacterial overgrowth is made by culture of
jejunal aspirate or by breath hydrogen testing.
Bacterial translocation is a phenomenon where intestinal
pathogenic microorganisms, which are normally resident
within the lumen of the intestinal tract, travel from the gut
lumen into local mesenteric lymph nodes, and from there
to distant sites, such as upper gastrointestinal tract,
thereby causing sepsis and septicemia [8,60-62]. Sepsis in
infants and children is defined as the systemic response to
a possible infection. Evidence of bacteremia or an infec-
tious focus is not required. The term septicemia is used
when organisms or their toxic products are identified in
the bloodstream, in other words, a pathogen is recovered
from blood cultures or identified [63].
Most studies of the pathogenesis of sepsis in animals have
been carried out shown that gut mucosa is particularly
susceptible to injury through a variety of mechanisms,
such as decreased mucosal blood flow, increased oxygen
demand, decreased oxygen delivery, and reperfusion
injury [64]. Sepsis is also associated with metabolic and
inflammatory response to trauma or surgical illness. It has
been suggested that the neuroendocrine response to sepsis
and trauma results in metabolic changes; and inflamma-
tory mediators released from wound itself or from a septic
focus may play a part in these changes.
It is also widely believed that these infectious complica-
tions are related to the central venous access devices
because the most recurring infection was reported as line
infection [8,58,60,65,66]. However, it has been suggested
that lipid emulsions of TPN may impair host defense, and
in particular the bactericidal and migratory functions of
the neutrophil polymorhonuclear (PMN) granulocyte in
infants receiving TPN [7,51,60,67-69]. A large case-con-
trol study [70] involving 882 infants in two neonatal
intensive care units, and one experimental animal study
[71] conducted suggest that administration of lipids in
parenteral nutrition regimens may cause phagocyte dys-
function, resulting in infectious complications such as
bacteremia, pneumonia, and wound abscesses. In addi-
tion, these studies also suggest that the lipid component
of TPN, which constitutes only long-chain triglycerides,
possesses immunosuppressive properties that interfere
with binding of interleukin 2 (IL-2), a product of activated
T (helper) cell or cytokine, to its cellular receptor and
impairs host defense, in particular the bactericidal and
migratory functions of the neutrophil polymorphonu-
clear (PMN) granulocyte [50,69-72]. However, three ran-
domized control clinical trials [73-75], and a case study
with 4 patients [76] did not show that intralipid in TPN is
associated with any immunosuppression. Interestingly, in
contrast to others, one of the randomized control trials
[73] showed that, rather than being immunosuppressive,
lipid emulsions of TPN had immunostimulatory
properties.
D-lactate acidosis
Bacterial overgrowth frequently complicates, especially
when the ileocecal valve is absent and the dysmotility is
present in the remaining bowel loops. In the colon, unab-
sorbed carbohydrates undergo bacterial fermentation to
D-lactate, short-chain fatty acids (acetate, propionate and
butyrate), which can not be metabolized by D-lactate
dehydrogenase; and these small molecules are absorbed
from colon, "carbohydrate salvage" [21,77]. Absorption
of this metabolite (D-lactate) may cause neurological
symptoms, metabolic acidosis with increased anion gap
in these patients [55]. It is called, "D-lactic acidosis Syn-
drome."  The episode of this syndrome causes patients
develop slurred speech, ataxia, and altered affect. These
patients appear "drunk." This condition is resolved after
placing patient on a diet with restricted carbohydrate
intake and metronidazole [23].
Methods
In this review, a descriptive systematic, non-quantitative
literature review was conducted using methodological
guidelines [78-80]. A systematic review is a technique that
uses systematically guided strategies to locate, select and
critically appraise relevant original studies for its subjects,
and summarizes the results that address a specific clinical
question from studies that are included in the review. It is
either descriptive (non-quantitative) when results of pri-
mary studies are summarized, but not statistically com-
bined, or quantitative, in which statistical methods areBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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used to combine results, also known as meta-analysis [80-
83].
A descriptive systematic review is also called a synthesis of
literature. This form of literature synthesis involves tabula-
tion of study characteristics and results to summarize their
findings in an area, and it also leads to new conclusions
and knowledge as a result of systematically pulling
together the fragmented results from single
studies[80,84].
Selecting and appraising studies for systematic review
To select and assess the methodological quality of the
research studies to be included in this review, the author
used a list of standardized criteria or the guidelines (Table
1) proposed by a group of researchers [78,82,85-89].
Studies were excluded if their published method section
was not clear or absent; TPN was not used; study out-
comes were not mucosal immunity related; or partici-
pants were not children.
Research question
To what extent does long-term TPN affect the intestinal
immune system of infants who undergo bowel resection
with no enteral nutritional support?
Search strategies
For the purpose of this paper, searches of the following
resources were used to do a comprehensive and exhaus-
tive literature search: 1) Electronic bibliographic data-
bases, 2) Reference lists from relevant primary and review
articles, 3) The Internet, 4) Hand-searched journals, and
5) Unpublished studies, such as Thesis and Dissertation
Abstracts [80].
A literature search was conducted using the following
online databases: OVID Databases (MEDLINE, BIOSIS,
CINAHL,  Current Contents, HealthStar, OVID Full text
journal articles), Cochran Library, Dissertation Abstracts,
Thesis, PubMed, Web of Science, Evidence-Based Medi-
cine, Evidence-Based Nursing, Journal Citation Reports,
MD Consult, Academic Search, CancerLit, and Journal
Collection Databases (Academic/IDEAL, Blackwell Sci-
ence, Elsevier, and SpringerLink).
The newer articles provided a reference list of citations of
previous articles. The research covered the years from
1990 through 2001 for original articles published in Eng-
lish. The following subject heading terms were included:
Total parenteral nutrition, bacterial translocation, immu-
nity, infant, children, short bowel-syndrome, short gut
syndrome, intestinal immunity, epithelial permeability,
immunonutrition, hyperglycemia, and sepsis. To prevent
this systematic review from publication bias, unpublished
studies were searched via Dissertation Abstract Online
(FirstSearch) database, and one unpublished thesis rele-
vant to this review was included [90].
Sample
In this systematic review, 12 published studies using
quantitative methods met the clinical trials criteria. In
addition, one unpublished study was included in this
review. These 13 studies included a total of 414 infants
and children between the ages approximately 4 months to
17 years old, and 16 healthy adults as controls. One of the
13 clinical trial samples was not counted because the
same sample was used for secondary analysis [58,60].
Although high quality, well-designed study, or the pre-
ferred research design for a review would be the one that
randomly allocates (concealing the assignment code) the
Table 1: Study selection criteria
Review Question:
To what extent does long-term TPN affect the intestinal immune system of infants who undergo bowel resection with no enteral nutritional 
support?
Population Were study patients pediatric age groups between newborn to 17 years old?
Did study patients have intestinal resection prior to TPN given?
Did study patients have documented bacterial infection after TPN started?
Did study patients have documented impaired mucosal immunity after TPN started?
Study Intervention Did at least one study group received Intravenous (IV-TPN?
Did study group received IV-TPN more than10 days?
Control Intervention Did one study group receive enteral feeding, but no IV-TPN?
Outcomes Was one of the measured outcomes documented as bacterial translocation, villi atrophy, impaired 
immuno-function, and death?
Note. Modified Table from "Selecting and appraising studies for systematic review," by M. O. Meade and
W. S. Richardson, 1997, Annals of internal medicine, 127 (7), p. 531-537 [86]. Copyright 2002 by the American College of Physicians-American 
Society of Internal Medicine. Adapted with permission.BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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participants with the condition of interest to alternative
therapeutic interventions, but when prospective rand-
omized clinical trials (PRCT) are not possible to find or
not available, NHS Center for Review and Dissemination
Guidelines suggest that the next best available evidence
should be considered based on the hierarchy of study
designs, which are from highest to lowest level: 1) pro-
spective experimental studies (e.g. randomized control
trial with concealed allocation), 2) experimental study
without randomization (quasi-experimental), 3) observa-
tional study with control group, a) cohort, b) case-control
studies, 4) observational studies without control group, a)
cross-sectional, b) before-and-after study, c) case series,
and 5) expert opinion [80,91,92]. In this review, the fol-
lowing available research designs are included: two pro-
spective experimental-control clinical trials [90,93], one
case-control [94], two cohort studies [58,60], three in-vitro
studies [7,51,67], one case study [95], and four retrospec-
tive medical chart reviews [5,96-98]. The studies were
published between 1993 and 2001 in pediatric journals,
annals of surgery, nutritional science journals, and
immunology.
The descriptive methodological and characteristics of the
samples are given in Table 2.
Data analysis
To collate and present the extracted data, a coding sheet
was used to collect information or study characteristics
that included both demographic and methodological
from the retrieved primary studies [79,99]. The results of
the retrieved primary studies were reviewed and summa-
rized in a coherent manner by using the NHS Center for
Reviews and Dissemination [80] non-quantitative data
synthesis guidelines, and classifying and structuring proc-
esses [100]. The data synthesis processes involve catego-
rizing and classifying extracted data results, tabulation of
each characteristic of the study and the major findings
related to TPN, and then drawing a conclusion or making
a coherent integrated report from the individual studies.
Once the results were extracted, they were organized, and
then categorized into similar themes. For example, the
results related to sepsis, septicemia, bacterial overgrowth
and bacterial translocation are grouped under sepsis. Five
major themes were found and organized based on the
most frequent reports.
Results
Five themes were identified: 1) sepsis, 2) impaired
immune functions: In vitro studies, 3) mortality, 4) villous
atrophy, 5) duration of dependency on TPN after bowel
resection. Table 3 provides the demographic characteris-
tics of the studies included in this systematic review.
Table 2: Methodological Characteristics of the Clinical Trials Included in This Systematic Review
Studies Discipline Year Publication Country Funding Trial Type (Setting) Participants
Andorsky et al. [96] Surgery 2001 J. Pediatrics USA Yes Retrospective (Hospital) Neonates
Okada, Klein, Pierro, et al. 
[20]
Pediatric Surgery 1999 J Pediatric Surgery UK Yes In Vitro, (Hospital) Infants and 
adults
Okada, Klein, van Saene, et 
al. [7]
Pediatrics 2000 Annals of Surgery UK Yes In Vitro, (Hospital) Infants
Okada, Papp, et al. [19] Pediatric Surgery, 
Immunobiology
1999 J Pediatric Surgery UK Yes In Vitro (Hospital) Infants and 
adults
Bines et al. [95] Gastroenterology & 
Clinical Nutrition
1998 J. Pediatric 
Gastroenterology 
and Nutrition
Australia Yes Case study (Hospital) Infants and 
children
Sondheimer et al [97] Pediatrics 1998 J. Pediatrics USA No Retrospective (Hospital) Neonates
Kaufman et al. [98] Pediatric 
Gastroenterology & 
Ped. Surgery
1997 J. Pediatrics USA Yes Retrospective (Hospital) Infants and 
children
Pierro, van Saene, Donnel, 
et al. [17]
Pediatric Surgery 1996 Archives of Surgery UK No Cohort study (Hospital) Infants
Pierro, van Saene, Jones, et 
al [18]
Pediatric Surgery 1998 Annals of Surgery UK No Cohort study (Hospital) Infants
Weber [94] Pediatric Surgery 1995 J Pediatric Surgery USA No Case-control (Hospital) Infants
Chaet et al. [5] Pediatric Surgery 1994 J Pediatric 
Gastroenterology 
& Nutrition
USA No Retrospective (Hospital) Children
Rossi et al. [93] Pediatric 
Gastroenterology
1993 Digestive Disease 
and Sciences
USA No Experimental-Control 
(Hospital)
Infants and 
children
Dahlstrom [90] Pediatrics 1988 Unpublished Thesis Sweden Yes Experimental-control 
(Hospital)
Infants and 
childrenBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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Table 3: Demographic characteristics of individual clinical trials included in this review
Studies Participants (Age) Interventions Results
Pierro, van Saene, 
Jones et al. (1998) 
[18]
94 infants on PN (median age 37 
weeks)
94 infants were on TPN. Throat 
and rectal swabs (surveillance 
cultures) were obtained before 
and twice a week after TPN 
started. Cefotaxime and 
metronidazole were given for 
prophylaxis, then blind therapy 
with a combination of Gentamicin 
and teicoplanic was given at the 
onset of sepsis. Blood cultures 
(central/peripheral) were sent.
41 patients (44%) on PN for 30 days, developed 
abnormal carriage. Among these carriers, 2 infants 
developed oropharyngeal E. Coli followed by 
Klebsiella spp, enterobacter spp, and Pseudomonas 
aeruginosa. 9 infants had blood cultures positive 
with enterococci, E. Coli, Klebsiella, Candida, and 
coagulase (-) staphylococci.
Pierro, van Saene, 
Donnell et al. 
(1996) [17]
94 infants, median gestation was 
37 weeks
Surveillance cultures of 
oropharynx and gut were obtained 
at the start of TPN and thereafter 
twice a week. Blood cultures 
(central/peripheral) were sent.
15 infants developed sepsis. 10 patients 
experienced septicemia. 6 patients had bacterial 
translocation, and overgrowth of bacteria observed 
in 9 patients.
Andorsky et al. 
(2001) [96]
Total of 30 infants with SBS (age 
<30 days) NEC = 13, Intestinal 
atresia = 9, Gastroschisis = 5, 
Malrotation/volvulus = 3
Median residual small bowel length 
was 61 cm. All infants were on 
TPN. The shortest duration of PN 
use was 101 days, and the longest 
was 3287 days, and median was 
245 days.
Of the 30 patients in the study, 20 (67%) were 
weaned from PN; 9 of the 10 TPN-dependent 
infants died from infection, cardiac arrest while 
receiving TPN.
Okada, Klein, van 
saene et al. (2000) 
[7]
41 babies enrolled (<4 mos. old). 
Gastroschisis = 11, (NEC) = 7, 
intestinal atresia = 3, 
diaphragmatic hernia = 2, 
esophageal atresia = 2, infant with 
no GI problems = 11, control 
infants = 5, and healthy adult 
volunteers (control) = 5.
5 infants receiving TPN for more 
than 10 days. 5 infants on normal 
enteral diet. Coagulase-negative 
staphylococci were added to 
whole blood from control patients 
receiving TPN.
Body weight was significantly lower in patients 
receiving TPN. The blood from control group 
killed 65% of the coag-neg. Staph, while the blood 
from long term TPN group failed to kill this 
organism.
Okada, Klein, 
Pierro et al. (1999) 
[20]
Surgical infants (NEC, 
gastroschisis)= 5, infants 
(control)= 5, healthy adults 
(control)= 5.
5 surgical infants on long term 
TPN (>10 days), 5 infants on 
normal enteral diet, 5 healthy 
adults.
The percentage of bacteria killed by the neutrophils 
increased with time. However, the ability of killing 
was significantly lower in infants on TPN.
Okada, Papp, et al. 
(1999) [19]
5 enterally fed infants (age<6 
mos), and 6 healthy adults
Fasting blood samples:
A) 10 ml normal saline (N/S)
B) 0.1 ml TPN in 9.9 ml N/S
C) 1 ml TPN in 9 ml N/S
D) 10 ml TPN
In infants, 1 ml of TPN in 1 ml blood produced a 
significant decrease in TNF-α production.
Weber (1995) [94] 21 infants and children with short 
bowel length (<80 cm) on TPN 
through central line. 20 infants 
without SBS (13 NEC, 4 atresia, 1 
gastroschisis, 2 volvulus) had 
surgery
No enteral feeding for 7 to 14 days 
during the post-op period. Blood 
cultures from central line and 
peripheral line were sent to 
identify the organism
6 patients had 8 separate episodes of sepsis before 
enteral feeding was began. After enteral feeding 
started, 16 patients had 67 episodes of bacteremia.
Chaet et al. (1994) 
[5]
32 children with SBS 
Gastroschisis = 3 Volvulus = 5, 
NEC = 8, Atresia = 8, 
Hirschprung's = 5
32 children with residual small 
bowel length <100 cm (range 14-
94, median 40). All patients 
required TPN support for 
minimum 2 months. 10 patients 
were on TPN for>3 years.
4 patients died. Two of these deaths were from 
complications of TPN, and other 2 had pneumonia 
and respiratory failure secondary to broncho-
pulmonary dysplasia. All four patients were TPN 
dependent up to the time of their deaths. One of 
these death patients bowel length was 30 cm and 
ICV was intact while the other did not (bowel 
length, 15 cm).
Kaufman et al. 
(1997). [98]
49 neonates with SBS, NEC = 20, 
Atresia = 12, Gastroschisis = 9, 
Volvulus = 8.
Infants with SBS required TPN for 
more than 3 months after initial 
surgery. Oral feeding was 
permitted in small volumes. 
Patients went home with TPN.
42 patients were able to wean completely from 
TPN. Bacterial overgrowth was diagnosed in all 7 
children who were receiving TPN. Occurrence of 
bacterial growth was related to small bowel length. 
6 of them died.
Sondheimer et al. 
(1998) [97]
44 infants NEC = 14, Atresia = 6, 
Gastroschisis = 4 Volvulus = 2, 
unknown = 10
Almost half of 32 infants had 50% 
or more of the estimated intestinal 
length resection. The remaining 12 
infants had 10-50% of bowel 
resection.
Of the 44 patients, four patients have died from 
liver failure while on TPN. Seven patients depended 
on TPN from 40 to 129 months. The rest, 27 
patients were off TPN after 36 months of age. 
Outcome of 10 patients unknown.BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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Sepsis
Six of the 13 trials reported bacterial overgrowth, sepsis, or
septicemia [58,60,90,94,96,98]. In the first study, [96]
investigators reported that two children died from gram-
positive central venous catheter infections. In the second
study [98], researchers compared a total of 49 neonates
with 7 SBS who were on TPN and 42 weaned children. It
was ascertained that the occurrence of bacterial over-
growth was related to small bowel length. Eleven TPN-
weaned subjects who had bacterial overgrowth had a
mean bowel length of 54 cm as compared to 105 cm in
those without bacterial growth. In Pierro and colleagues'
study [58], 41 children whose surveillance cultures devel-
oped abnormal carriage. These investigators stated that
infants receiving TPN are at a very low risk of developing
sepsis and septicemia as long as their surveillance cultures
reveal normal flora only. Conversely, the presence of
abnormal PPM in the throat and/or the gut increases the
risk of sepsis and septicemia to about 25% of the popula-
tion art risk. They have also stated that the sicker and more
physiologically stressed infants would not regain normal
gut function as fast as neonates who were doing clinically
better.
In the third study [60], the purpose of the investigation
was to demonstrate an association between microorgan-
isms that were carried in the digestive tract and present in
the blood of infants with sepsis who were receiving TPN.
Sepsis occurred in 15 patients (43 episodes) and 10
patients experienced septicemia (24 episodes). Six infants
had 15 episodes of bacterial translocation due to E. coli,
Klebsiella, Candida species and enterococci. Eight patients
had nine episodes of septicemia caused by coagulase-neg-
ative staphylococci. The researchers concluded that there
was an association between septicemia and elevated
serum bilirubin level, indicating TPN related cholestasis.
Dahlstrome [90] investigated a total of 29 children, most
of whom had SBS and had been on TPN for 2 years. Chil-
dren receiving TPN for an average of 2 years developed
low biochemistry levels. The children were divided into
two groups. The children in group I were estimated to
have absorbed less than 5% of their daily caloric intake
from the intestinal tract, while intake in the children in
group II was 30-70%. Based on previous animal studies,
the investigator predicted that the low lymphocyte count
was related to extensive bowel resection, (the average
bowel length of group I was<25 cm). Eleven of these chil-
dren eventually died from TPN related sepsis, septicemia,
central line infections, or cholestatic liver diseases.
Impaired immune functions: in vitro studies
In three in-vitro control studies, investigators elucidated
that long-term TPN in infants suppresses specific mecha-
nisms of immune functions [7,51,67]. In the first study,
Okada and colleagues (1999) investigated the effects of
TPN solution on neutrophil phagocytosis and whole-
blood cytokine production in response to coagulase-neg-
ative staphylococci in an in vitro challenge in five enterally
fed infants (age<6 months) and 6 healthy adults. They
found that in infants, after 2 hours of incubation with a
physiological dose of TPN (1 µ of TPN in 1 ml of blood)
there was a significant decrease (P < 0.05) in tumor necro-
sis factor alpha (TNF-α) production.
Bines et al. (1998). 
[95]
4 patients with SBS (6 months to 
5 yrs), NEC = 2, Volvulus = 1 
Hirschprung = 1
All patients had central line. 
Patients received pregestemil 
formula via continues GT, while on 
TPN, then study formula 
(Neocate) was given
All patients were able to discontinued TPN within 
15 months of initiating the study formula. After 
tolerating enteral study formula, morbidity and 
hospitalization reduced dramatically.
Rossi et al. (1993) 
[93]
7 children, ages 9 months to 17 
years. 3 children with 
inflammatory bowel disease (IBD) 
were on TPN for one month. 4 
children with SBS on TPN for 7 to 
54 months. 22 infants (control) 
on normal diet.
All patients while on TPN for one 
month, underwent to intestinal 
endoscopy and biopsy. Of these 
patients: 7 on TPN, and had upper 
intestinal biopsy. 4 patients 
required TPN for >9 months
Biopsies from patients in the IBD group didn't 
show atrophy. 3 patients on long-term TPN for 
SBS had very mild (grade I) villus atrophy.
Dahlstrome 
(unpublished, 
1988) [90]
29 children (4â€“111 month) SBS 
= 11/9 on TPN/ PPN (small 
bowel<25 cm) pseudoobstruction 
= 7 on PPN immunodeficiency = 
1 radiation enteritis = 1 28 
(control) healthy children (10 
USA and 18 Swedish the same age 
group)
Group I children absorb <5% of 
their daily caloric intake; Group II 
children was 30-70%. Home-TPN 
was given each night, and children 
were encouraged to eat daytime as 
much as possible for an average of 
two years.
After two years of long-term TPN, children had 
abnormal lymphocyte count, low levels of serum 
albumin and protein in-group I. Four children 
developed selenium deficiency, and 15 children on 
PN for 3 yrs had significantly low Hb and Hct 
compared to controls. Eleven of 29 children died 
from low lymphocyte count. Seven died (5 from 
SBS, 1 from pseudoobstruction, 1 from immune 
deficiency), 4 from TPN induced cholesistatic liver 
disease and from bacterial septicemia.
PPP:Partial parenteral nutrition, PN: Parenteral nutrition, Hb: Hemoglobin, Hct: Hematocrit
Table 3: Demographic characteristics of individual clinical trials included in this review (Continued)BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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The other two in vitro controlled-clinical trials focused on
the cellular mechanism of neutrophil dysfunction, and
the whole blood bactericidal activity against coagulase
negative staphylococci in the infants receiving TPN [7,67].
These investigators used an in vitro-controlled whole
blood model to measure the host bactericidal activity
against coagulase-negative staphylococci. When research-
ers added coagulase-negative staphylococci to whole
blood drawn from control patients receiving enteral feed-
ing, the median killing of coagulase-negative staphyloco-
cci was 65%. In contrast, blood from infants receiving
long-term TPN failed to kill this organism as effectively.
Infants on long-term TPN had the lowest levels of both
whole blood and intracellular killing of coagulase-nega-
tive staphylococci due to a defect in neutrophil function.
These investigators reported that there was a negative lin-
ear correlation between the duration of TPN in days and
killing of coagulase-negative staphylococci (P = 0.002).
For every additional week of TPN, there was a 7% reduc-
tion in killing of coagulase-negative staphylococci. These
investigators also noted that there was a significant posi-
tive correlation between neutrophil count and killing of
coagulase-negative staphylococci (r = 0.80, P = 0.001).
Mortality
A total of 34 TPN complicated deaths were reported in five
of the 13 clinical trials. Of these 34 deaths, 7 children died
from SBS, 12 from sepsis, respiratory infections, and low
immune deficiency, and other 15 from liver failure
[5,90,96-98].
Duration of dependency on TPN after bowel resection
There were only three studies, retrospective and case study
that showed the dependency on TPN in infants who had
undergone resection of the small intestine [95-97]. As
reported in these studies, there were only 17 children who
were totally dependent on TPN, and nine of them died
while on TPN. In one of these studies, investigators also
noticed that no child successfully discontinued TPN after
36 months of age [97]. They concluded that children
dependent on TPN at or more than 36 months of age are
permanently dependent on TPN. Andorsky and his co-
workers [96] also emphasized that residual bowel length
was highly correlated with duration of TPN. Their conclu-
sion was that remaining functional small bowel length
was an independent predictor of successful weaning.
Although most children had difficulty being weaned from
TPN in other studies, Bines and her co-workers [95] were
able to wean all four children from TPN within 15 months
of initiation of a study formula. They used an amino acid-
based complete infant formula (Neocate, SHS Inc, Rock-
ville, MD, USA) as enteral feeding. Small bowel length of
these children was documented between 40 cm to 80 cm
with no ileocecal, and in only one child had 13 cm with
ileocecal present. All patients had repeated esophagogas-
troduodenoscopy and colonoscopy or jejunoscopy with
findings of mild, nonspecific neutrophilic inflammation
involving areas from biopsy specimens from upper and
lower intestinal tract.
In addition, two other studies used enteral formulas while
children were on TPN. Andorsky and colleagues [96] fed
the patients with continuous breast milk or protein
hydrolysate formula. Of the 30 patients in the study, 20
were weaned from TPN. Based on their report, median
residual bowel length was 61 cm, and ileocecal valve was
preserved in 57% of the patients. There was a significant
high correlation between use of breast milk and shorter
the duration of TPN. Infants who received breast milk
were weaned from TPN in 290 days versus 720 days in
non-breast-fed infants.
Villous atrophy
In two separate clinical trials, researchers [93,95] exam-
ined whether the effects of TPN on the intestines of chil-
dren are similar to those reported in animals. In the Rosi
and colleagues' study, a total of 32 children (ages 9
months to 19 years) were involved. Based on the biopsy
results, the investigators reported that 3 of the 4 patients
receiving long-term parenteral nutrition for short-bowel
syndrome (TPN >7 months) had mild villous atrophy.
Biopsies from 3 patients in the inflammatory bowel dis-
ease (IBD) group (TPN = 1 month) did not exhibit atro-
phy. Bines and colleagues [95] also reported similar
results; in their study only one of four children (bowel
length, 40 cm) had partial villous atrophy of the small
intestinal mucosa.
Discussion
Systematic reviews focus on empirical studies and seek to
summarize past research by drawing overall conclusions
from many separate investigations that address related or
identical hypotheses [101]. The purpose of this descrip-
tive systematic review was to assess the literature docu-
menting whether TPN negatively influences gut barrier
function and is associated with increases in intestinal bac-
terial overgrowth, bacterial translocation, increases in
mucosal permeability, decreases in S-IgA levels, and
changes in mucosal architecture in infants and children
after small bowel resection. Thirteen clinical trials in chil-
dren from 1990 to 2001 examined the effects of TPN on
infection, mortality, impaired intracellular immune func-
tions, villous atrophy, and long-term TPN dependency.
These studies were conducted in four countries from vari-
ous disciplines; they ranged in size from 4 to 94 children,
and age from approximately 4 months to 17 years old,
with the majority of children spending time in hospital.BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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Numerous experimental studies suggest that long-term
TPN has harmful effect. Evidence in experimental studies
about TPN's effects on mucosal immunity and villous
atrophy is very convincing [9,14]; however, findings in
human subjects were inconsistent. Although animal mod-
els provide us wealth of evidence and continue to offer
valuable information to apply to clinical conditions, Rossi
and coworkers [93] argue that extrapolating these results
to apply to the human model is inappropriate. Their study
results showed that infants with SBS on TPN for more
than 9 months had only minimal grade villi atrophy. They
concluded that humans are more resistant to hypoplastic
intestinal changes induced by TPN; and effects in humans
seem to require longer periods of TPN. In adults, 203 sur-
gical patients who had at least 10 days of preoperative
TPN without enteral nutrients, no significant decrease in
villous height or increase in bacterial translocation were
noted compared with those on enterally fed controls
[102]. Guedon and colleagues [103] performed biopsies
in the duodenum of seven adults (all with inflammatory
bowel disease) before TPN, after about 3 weeks of TPN,
and after discontinuing TPN and restarting oral feedings.
They noted no change in gross villous morphology with
only moderate decrease in microvillus height after 21 days
of TPN. Buchman and colleagues [3], however, found a
significant decrease in villous height after 2 weeks of TPN
study involving eight healthy volunteers. Although
mucosal thickness decreased significantly, in contrary to
animal studies, villous architecture was preserved after
TPN; and five days of enteral refeeding was sufficient to
reverse the intestinal morphologic changes. Pironi and
colleagues [104] performed endoscopic biopsies in 2
adult patients who underwent long-term TPN for the
treatment of a postoperative enterocuteneous fistula, and
their results showed changes in villous height and crypth
depth after 2 and 3 months of TPN; two months after oral
refeeding, the values of morphometric parameters were
significantly greater than those observed after TPN and
were similar to those controls. Groos and colleagues [105]
also conducted a study involving 20 adults to investigate
whether TPN causes morphological changes in intestinal
mucosa of human adults similar to those observed in ani-
mals experiments. They found jejunal mucosal atrophy,
and a remodeling of luminal surface architecture with dis-
appearance of cell shedding.
Bacterial translocation
In this review, bacterial translocation was reported only in
one study [60]; it stated that 10 children experienced 24
episodes of septicemia, but only 6 out of 94 infants had
bacterial translocation. Andorsky [96] reported that 9 of
10 children died from infection while on TPN, but no
statement has been found whether those children died
from infection or from other causes. In a large review, Lip-
man [106] critically assessed the effects of TPN and enteral
nutrition, and did not find any convincing evidence that
TPN promotes bacterial translocation or enteral nutrition
prevents bacterial translocation in humans.
In a large critical review, Lipman [107] examined the exist-
ence of bacterial translocation and the effects of enteral
nutrition on bacterial location using both animal and
clinical trials. He did not find any evidence supporting
that enteral nutrition preserves gut barrier functions and
prevents bacterial translocation. He concluded that bacte-
rial translocation is an independent of intestinal structure;
and also the villous atrophy seen may be species specific.
Pierro and colleagues [58] used throat and rectal swabs as
surveillance culture samples twice a week to investigate
whether carriage of abnormal flora was associated with
increased risk of sepsis and septicemia in children receiv-
ing TPN; and they concluded that infants receiving TPN
are at very low risk of developing sepsis or septicemia as
long as their surveillance cultures reveal normal flora
only. However, the presence of abnormal PPM in the
throat or the gut increases the risk of sepsis and septicemia
by 25 % [58]. Surveillance samples are defined as speci-
mens obtained from body sites were PPM are normally
carried by the digestive tract.
IgA
The importance of enteral stimulation on the mucosa-
associated lymphoid tissue (MALT) system was studied in
neonates who died soon after birth. Histological examina-
tion of the biopsies showed that infants who received
enteral stimulation showed clear evidence of B cells and T
cells within the mucosa; whereas, parenterally fed infants
who died had a villous atrophy. Gut and bronchus sam-
ples were obtained and related to time of death of infants
who died of sudden infant death syndrome between two
weeks and 90 moths after birth. IgA plasma cells first
appeared in the gut and later in the bronchi as the system
matured. Plasma cells increased rapidly over time as IgA
plasma cells predominated by three weeks in the gut and
six weeks within the bronchi [108].
In this review, none of these studies have tested whether
TPN decreases S-IgA levels in intestinal mucosa causing
increased bacterial translocation. Although there was only
one study focused on the changes in IgA production dur-
ing TPN in 8 healthy human volunteers [109], the results
of this study did not show significant differences in the
number of immunoglobulin-containing cells. Intestinal
immune function was not affected by 2 weeks of TPN.
Woodcock and colleagues [61] also investigated whether
bacterial translocation is associated with changes in gut
immune function in 22 adult patients (11 of whom were
positive bacterial translocation and 11 negative). How-
ever, these patients were not on TPN. The study resultsBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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showed a significant increase in immune functions, espe-
cially higher numbers of plasma cells and IgA and IgM val-
ues in small bowel mucosa of patients in whom bacterial
translocation has been positive.
Hyperglycemia
In this review in vitro studies on infants and children dem-
onstrate that TPN inhibits functions of neutrophils,
cytokines, and bactericidal activity of phagocytosis
[7,51,67]. Investigators found that cytokine production
after bacterial challenge was directly impaired by addition
of TPN solution. In these patients calorie intake varied
from 100 to 130 kcal/kg/day; and TPN emulsion con-
sisted of carbohydrate 15 to 18 g/kg/day, amino acids 2-3
g/kg/day, and fat 3 to 4 g/kg/day. Although these studies
do not state whether these children's serum glucose levels
were high, perhaps TPN-induced hyperglycemia may have
also contributed to dysfunction of neutrophils. It has been
hypothesized that the elevation of blood glucose in
patients receiving TPN may be associated with complica-
tions, such as immunosuppression [110]. Glucose con-
centrations above 220 mg/dL have been shown to
glycosylated immunoglobulins, causing a significant
reduction in opsonic activity, which adversely affects
wound healing and immunity [111].
There is a large body of evidence demonstrates that there
is a positive correlation between high serum glucose levels
and increased infection rates in acutely ill patients in crit-
ical care medicine. Insulin therapy seems to be beneficial
in sepsis patients [54]. Rassias and colleagues recently per-
formed two comparative randomized control clinical
trials one involving 30 non-diabetic adult cardiac patients
(15 in each group) [112], and the second clinical trial
involving 26 diabetic adult cardiac patients (13 in each
group) [113] who were scheduled for elective cardiac sur-
gery with cardiopulmonary bypass surgery. The experi-
mental group received intensive insulin treatment while
the control group received standard insulin therapy. They
found a significant increased in neutrophil count and
neutrophil functions in intensive insulin therapy group.
They suggest that hyperglycemia leads to increased
endothelial adherence of neutrophils and may lead to
lower white blood cells in hyperglycemic patients.
Since its introduction, TPN has been a life saving nutrient
to severely malnourished patients. It was believed that "if
some nutrition is good, more is better" [114]. Even in
treating diabetic patients in the hospital, for decades, an
oral tradition was passed down from clinician to clinician,
"keep the patient a little sweet" [115]. It has been recently
recognized that in the presence of sepsis an increased
intake of energy, or overfeeding the patients with carbohy-
drates or fats, increases the risk of complications, which
contributes to hyperglycemia and sepsis. This TPN-
induced and/or physiological stress-induced hyperglyc-
emia may have also contributed to increased rates of sep-
sis [39,114]. In a careful analysis of stress-induced
hyperglycemia in 102 non-diabetic patients receiving
TPN, subjects who received dextrose at >5 mg/kg/min,
had 50% chance of developing hyperglycemia [116]. In
contrast, dextrose infusion at < or = 4 mg/kg/min, risk was
substantially reduced. Therefore, to prevent hyperglyc-
emia and infection complications in hospitalized
patients, TPN dextrose infusion rates should be at < or = 4
mg/kg/min [117].
Two randomized prospective clinical trials [118,119] of
aggressive insulin therapy now have revolutionized our
current philosophy about treating critically ill hospital-
ized patients [53]. In the first study, a total of 620 patients
(306 patients randomized to treatment with insulin-glu-
cose infusion followed by multidose subcutaneous insu-
lin for ≥ 3 months and 314 to conventional therapy)
[119]. In the second study, Van den Berghe and coworkers
[118] conducted a large prospective, nonblinded, rand-
omized clinical trial (a total of 1548 surgical patients in
ICU) of intensive glycemic control (glycemic goal of 80-
110 mg/mL [4.4-6.1 mmol/L] compared with conven-
tional treatment (maintenance of blood glucose at a level
between 180 and 200 mg/dL). At the end of the study,
results showed that intensive insulin treatment reduced
episode of septicemia by 46%, and overall mortality rate
by 32% during their stay in ICU.
Hyperglycemia is commonly seen in stressed patients dur-
ing administration of TPN or other glucose-containing
solutions. Stress may also induce insulin resistance in adi-
pose tissue, liver and heart [120]. However, the treatment
of hyperglycemia starts only after glucose levels have
exceed 200 to 250 mg/dL (11â€“14 mmol/L) because it
was believed that avoidance of hypoglycemia and its
potential consequences is more important than glycemic
control while patients are hospitalized. The most recent
target range for plasma glucose in the hospital are: pre-
prandial = <110 mg/dl; peak postprandial = <180 mg/dl;
and for critically ill patients = 80-110 mg/dl [53].
Some studies reported that the complications during TPN
were associated with the residual or the remaining bowel
length in patients with SBS. The longer the residual small
bowel, the shorter the duration of TPN, and the fewer
infections [5,96]. The results of Dahlstrome's [90] study
revealed that children whose bowel length was <25 cm
developed very low levels of circulating lymphocytes caus-
ing immuno-competence due to very short bowel length,
and not ingesting the food antigens which are the main
stimulants of lymphocytic proliferation and immu-
noglobulin (IgG, IgA) synthesis. Dahlstrome predicted
that lack of ingested antigens might have caused the lowBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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circulating lymphoctes, which resulted in infection. He
found that enteral support in combination with TPN did
improve, but not normalize the plasma amino acid con-
centrations in the children investigated.
Enteral versus parenteral nutrition
It has been suggested that enteral stimulation is a required
component to protect gastrointestinal and respiratory
immunity via increased levels of mucosal IgA [15,121].
Enteral nutrition refers to nutrition either ingested orally
or delivered to the stomach or intestine by tube via
nasogastric (NG) tube, gastrostomy tube (GT), nasojeju-
nal (NJ) tube, or jejunostomy tube (JT). Evidence showed
that enteral nutrition is less expensive, but not safer, or
more physiologic than TPN [106]. In a prospective obser-
vational nursing study [122], 64 elderly patients who were
fed by an NG tube in an internal medicine. The type of for-
mula was not stated in the study, but based on this report;
most patients had electrolyte imbalances, tube
dislodgements, hyperglycemia, diarrhea, pulmonary aspi-
rations, and nasal ulcers. In another prospective observa-
tional study [123], a total of 153 critically ill patients also
were fed with NG tube. Before each feeding, gastric resid-
ual volume was checked by using 50-ml syringe by aspi-
rating the tube. The study results showed that there was a
negative relationship between high gastric residual vol-
ume and days in the hospital stay. High gastric aspirate
volume was associated with a higher incidence of nasoco-
mial pneumonia, a longer length of hospital stay, and
higher mortality.
Effects of early enteral feeding on bacterial translocation
In Weber's study [94], 21 infants and children with SBS
were begun with enteral feedings via continuous drip
technique with an elemental formula (Pregestemil:Mead-
Johnson, Evansville, IN), after 3 weeks of postoperative
period. Results showed that after enteral feeding began,
76 % of children had 67 episodes of bacteremia. The
investigator suggests that early enteral feeding increases
infection. However, Marik and Zaloga [124] performed a
systematic review of 15 PRCT included 603 patients to
evaluate the effect of early enteral nutrition on outcome of
critically ill and injured patients. The results of this study
showed that there was a significantly lower risk of infec-
tion in 19 % of the patients who received early enteral diet
compared with 41 % in the delayed group. This study con-
cluded that early feeding decreases infectious complica-
tions and length of hospital stay. In a large review, by
pooling data from four PRCT involving 142 patients who
had gastrointestinal cancer, Klein et al. [125] compared
early postoperative JT feeding with the usual advancement
of oral diet as tolerated. Based on the aggregated data,
there were no significant differences in postoperative mor-
bidity or mortality.
However, Daly et al. [126] performed a PRCT involving 85
adult the patients (41 on supplemented diet, 44 on stand-
ard diet) with cancer of upper gastrointestinal tracts. The
patients who were fed early postoperatively [on the first
postoperative day] via JT with a formula supplemented
with arginine, ribonucleic acids, and ω-3 fatty acids had
fever infections, minimal wound complications, and a
shorter duration of hospitalization compared to those
who received standard formula. Braga at al. [127] also per-
formed a PRCT involving 166 patients undergoing gas-
trointestinal surgery to evaluate the impact of the route of
administration of artificial diet, IMPACTÂ®  (Novartis
Nutrition, Bern, Switzerland) supplemented with
arginine, ribonucleic acid, and omega-3 fatty acids versus
standard diet on outcome. Their results showed that early
postoperative enteral infusion of nutrients is safe and well
tolerated and stimulates an early return of bowel function.
Immunonutrition
There has been a considerable amount of interest in recent
years in the use of alternative specific gut substrates. The
term immunonutrition has been coined to describe molec-
ular compound that, while being dietary components,
such as glutamine, arginine, ω-3 fatty acids, ribonucleic
acid, also influence immunologic response mechanisms
when added to standard TPN solutions or enteral nutri-
tion [128-130]. Glutamine, a nonessential amino acid, is
considered to be the principal respiratory fuel for entero-
cytes, colonocytes, lymphocytes, and macrophages, and is
a precursor for nucleotides synthesis and for glutathione,
an important antioxidant that may be protective in a vari-
ety of circumstances. It has been hypothesized that during
the stress, glutamine becomes conditionally essential
amino acid.
In the late 1980s, glutamine has been the most extensively
studied substrate in animal research, especially in rat TPN
model. It has been suggested that parenteral or enteral
glutamine supplements could dramatically effect on the
maintenance of GALT; and glutamine-enriched TPN sig-
nificantly attenuates the mucosal hypoplasia associated
with prolonged TPN following massive bowel resection
[131-134]. Therefore, it was hypothesized that glutamine
supplementation in human modal would have similar
effects [77]. Encouraged by findings in animal investiga-
tions, in 1991 Darmaun and colleagues [135] first time
reported a reduced rate of glutamine turnover in short
bowel syndrome [adult] patients, and in 1994 in pediatric
patients [136]. They suggested that the small intestine was
a target organ for glutamine utilization in both adults and
children. C.K. Ogle (unpublished, cited in Alexander,
1993) [137] also has shown that excess glutamine added
to culture media can improve antimicrobial killing by
neutrophils isolated from blood of burn patients and nor-
mal controls. Alexander also argues that infection can beBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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reduced 75% and hospital stay by 20% by immune
enhancement via enteral nutrition.
In the following years, many controlled trials and case
series were conducted to demonstrate the benefits of
immune enhancing substrates to the intestinal adaptation
process in patients with SBS during long-term TPN [138-
147]. The results of these published studies have been
conflicting. Although glutamine supplementation has
been shown to be value in pediatric patients [38,148],
Duggan and colleagues [149] conducted a randomized
double-blinded, controlled clinical trial of enteral
glutamine supplementation in 20 infants with SBS. At the
end of study, there was no significant difference in weight
and length gain between two groups. Two of nine infants
in the glutamine group developed urinary and blood-
stream infections. Overall, this study results showed that
glutamine supplementation was safe, but had no effect on
duration of TPN, tolerance of enteral feeds, or intestinal
absorption or barrier function. However, in a PRCT pilot
study Barbosa and colleagues [150] examined the toler-
ance and efficiency of glutamine in a pediatric intensive
care unit setting with nine mechanically ventilated infants
(treatment group = 5, and control group = 4). Their results
showed that tolerance to glutamine-supplemented diet
was good. Bacterial infections reported in 75% of the pla-
cebo population and 20% of the treated infants. There
were two deaths from microbial infection in control
group, suggesting a beneficial effect of glutamine.
However, Scolapio and colleagues [142,151] conducted a
series of double-blind, 6-week, placebo-controlled, cross-
over trial in 8 adult patients with SBS to assess: 1) the
effects of growth hormone, glutamine, and high-carbohy-
drate-low-fat (HCLF) diet on body composition, and 2) to
evaluate the potential mechanisms that might explain the
beneficial effects of immunonutrition treatment. Active
treatment consisted of subcutaneous recombinant human
growth hormone and oral L-glutamine. In this study, two
patients developed carpal tunnel syndrome that resolved
5 days after discontinuation of active treatment. Two
patients noted sleep disturbances while on active treat-
ment. Patients developed peripheral leg edema and
weight gain; this combination therapy resulted in a signif-
icant increase in sodium and potassium absorption. Two
studies [145,152] also reported similar findings in addi-
tion to severe hand pain, and gynaecomastia in a male
patient. Two systematic reviews [138,153], and two large
critical reviews [77,125] conclude that glutamine and
growth hormone at present time can not be recom-
mended in short bowel syndrome; more large-scale stud-
ies, or multicentered clinical trials are required.
Currently, two commercially prepared immune-enhanc-
ing enteral formulas are available in the market, IMPACT®
(Novartis Nutrition, Bern, Switzerland) containing
glutamine, arginine, dietary nucleotides and fish oil; and
Immune-Aid (McGaw, Irvine, CA) containing glutamine,
arginine, nucleic acids, and omega-3 fatty acids. Some
studies indicate that these immune-enhancing diets dem-
onstrated successful results or benefits in studies of sepsis,
immunity, altered intestinal permeability, inflammation,
including reduced mortality and the length of hospital
stay [154-156].
Some studies also show that the use of breast milk in SBS
contains high levels of immunoglobulin A (IgA), nucle-
otides, leukocytes, and other components that bolster the
neonate's immune system[20]. In a study, a continuous
infusion of small amounts of breast milk in infants with
SBS is also resulted in a shorter duration of TPN compared
to control group [96].
Overall, findings are inconclusive. Immunonutrition may
be species or patient specific.
Implications for evidence-based nursing practice
Multidisciplinary nutritional team
The successful management of infants and children with
SBS is demanding and requires a multidisciplinary
approach. The care of patients with SBS can become so
complex that many patients with SBS almost lose their
primary physician and become patients of multiple spe-
cialists. Long-term care is, therefore, best delivered by a
variety of healthcare professionals, including the gastro-
enterologists, surgeon, nurses, nutritional support team,
care coordinators, microbiologist or infection control
team, clinical chemist, pharmacists, social workers, and
psychologist with expertise in infant feeding difficulties.
Patients cared for in this way have better outcomes
[25,148,157].
Infants go through a critical developmental phase in feed-
ing at about 6â€“12 months, and those who do not
receive oral feeds at that time will loose the window of
opportunities for sucking and swallowing coordination,
and will have long-term eating difficulties [21,158]. In
addition, children fed enterally or parenterally may have
forgotten or never learned the association of with hunger,
oral feeding, and satiety; they develop "defensive oral
behaviors," such as gagging, choking, and vomiting. For a
sick child, if this important developmental phase is
ignored during the first year of life, flavor, texture, odor,
and extreme temperature can be overwhelming. It is
important that the pediatric nurses should consult pediat-
ric occupational therapist and speech therapist, and
behavioral psychologist to work with these children
[159].BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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Clinical management
The management of neonates and children with SBS con-
tinues to provide a major challenge for practitioners
[160]. A group of pediatric surgeons critiqued the current
clinical management of SBS in children, which is mostly
based on "trial and error" regimen. They strongly recom-
mended that prospective, randomized controlled trials
should be established, and an evidence-based rather than
a "gut-feeling" -based approach to be used in SBS chil-
dren, such as intestinal permeability and sugar absorption
tests, evaluation of adaptation by gut hormone produc-
tion, immunohistochemistry, and other new techniques
which are still in experimental stage [154]. Pediatric
nurses should, therefore, provide an evidenced-based
nursing care to these children with the support of APRN.
Hypersecretion is seen in infants and children during the
initial first 6 months after surgery and a start of enteral
feeding. The H2 blockers and proton pump inhibitors are
effective for reducing gastric fluid secretion, and therefore,
will also reduce fluid losses during this period [77,161].
The diagnosis of bacterial overgrowth is determined by
aspiration of the jejunum and demonstration of increased
bacterial contents by culture. Since this procedure is inva-
sive and infeasible in some sick infants, breath hydrogen
test can be used easily as noninvasive diagnostic test
[162]. The breath hydrogen test is an oral test that uses the
measurement of hydrogen in the breath to evaluate carbo-
hydrate malabsorption and bacterial overgrowth in small
intestine. Hydrogen gas is produced by bacterial
fermentation of undigested carbohydrate that reaches the
colon, enters the portal and systemic venous return, and is
then released in the breath. After fasting 4-6 hours, the
child ingests a load of carbohydrate (12 g/kg, maximum
50 g), and the end-expired air is collected in sealed plastic
bags by aspirating 5 mL of air after each breath to total of
20-30 mL via nasal prong attached to a face mask at timed
intervals up to 2 hr after ingestion. Malabsorption of any
carbohydrate can be evaluated. The child should not be
taking antibiotics at the time of the study because these
drugs alter the colon flora and suppress hydrogen gas pro-
duction [163-165]. In one of the clinical studies, investi-
gators used 50 mg 13C-xylose in children ages 3 to 12 years
for breath hydrogen test [166]. 13C-xylose is a safe, nonra-
diactive isotope that has recently been developed (Martek,
Columbia, MD). This study results showed that all
patients with bacterial overgrowth had positive breath test
results (100% sensitivity).
For infants prone to overgrowth, routine scheduled anti-
biotic treatment may be useful. D-Lactic acidosis has been
reported in children with bacterial overgrowth, causing
metabolic acidosis, drowsiness, and confusion. This diag-
nosis should be considered in a child with SBS who
presents with metabolic acidosis, high serum anion gap,
normal lactate level, and without urinary ketones [161].
Treatment for this syndrome is to start oral metronida-
zole, neomycin, vancomycin, and avoidance of "refined"
carbohydrates [77].
Dietary management
Optimal timing of the initiation of enteral nutrition has
not been established [161]. Patients who undergone mas-
sive bowel resection require TPN for the first 7-10 days.
American Gastroenterological Association (AGA), based
on the current literature review, suggests that nutritional
therapy should not be introduced until the patient is
hemodynamically stable and fluid management issues are
relatively stable.
Although the optimal formula for feeding infants and
children with SBS is not well established, elemental
amino acid based hydrolyzed formulas are suggested by
some clinicians and have been shown to be well tolerated
[95]. Dietary protein is first digested, and then absorbed
as dipeptides and tripeptides. Therefore, it was reasoned
that dietary protein provided in a predigested form would
be more readily absorbed [77].
A prospective, randomized, cross-over trial compared two
protein hydrolysate formulas given by continuous
nasogastric infusion to six malnourished infants with SBS
aged 1-13 months [167]. Although there was good toler-
ance for both formulas and satisfactory weight gain, and
also energy absorption was the same, but differences in
the amount of malabsorbed carbohydrate existed. These
researchers suggested that protein hydrolysate formulas
should be reformulated with a lower concentration of car-
bohydrates and a higher one of fat.
A controlled trial compared two feeding regimens, contin-
uous intragastric feedings and intermittent oral feeding, in
nine infants with protracted diarrhea and malnutrition
and two infants with surgically created short bowel [168].
Continuous nasogastric feeding caused significant
increases in enteral balance of the major nutrients,
whereas intermittent feedings resulted in negative or only
slightly positive enteral balance. There was also a signifi-
cant increase in body weight during the continuous feed-
ing as compared to the intermittent feeding. The authors
suggest that improved enteral balance can be achieved
with continuous feeding in infants with short bowel dis-
ease [168].
In infants under 1 year of age with SBS who might have
dilated gut, poor motility, or bacterial overgrowth,
increased epithelial permeability to food antigens occurs
frequently and may result in the development of allergic
reaction to any protein in the formula. In order to reduceBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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the risk of allergic injury to the gut, a hypoallergenic for-
mula, such as Nutramigen, Pregestemil(Mead Johnson
Laboratories, Evansville, IN), and Alimentum (Ross labo-
ratories, Columbus, OH), should be used during the first
year of life. To further decrease the risk of allergic reaction
in highly susceptible infants, an amino acid based for-
mula should be used. Neocate (SHS Inc, Rockville, MD,
USA) is the only one listed in this category for infants. Ele-
care (Ross Laboratories), which is quite similar to Neo-
cate, was formulated for use in children over 1 year of age
[169].
Initially slow introduction of continuous enteral feeding
via a nasogastric or gastrostomy tube feeding is beneficial
to reduce emesis, diarrhea, and maximally saturate carrier
proteins. Rationales for this that constant saturation of
mucosal digestive enzymes and transport carriers should
be optimize absorption. Regardless of the length of small
intestine, some oral, even if only 1 or 2 ml per day, and a
few ml in continuous fashion should be offered from an
early stage [158].
A diluted infusion is initiated continuously at low vol-
umes and increased to 0.67 cal/mL for infants less than 1
year of age or to 1.0 cal/mL in older children. Once the
final concentration is achieved in low volumes, enteral
feeding rates are advanced, and TPN rates are decreased
isocalorically every 1 to 3 days as tolerated [170]. A
marked increase in stool loss by 50 % is usually contrain-
dication to advancing enteral feedings. There is no agree-
ment on the amount of stool output that should be
accepted. Limits should be imposed on feeding once the
stool output exceeds 45 ml/kg per day [161]. However, a
higher volume of stool output may be acceptable by some
clinicians [171]. If stool losses greater than 45 ml/kg/day
or ostomy output strongly positive for reducing sub-
stances suggest that enteral feeding advancement should
be slowed. Careful fluid and electrolyte management is
essential as dehydration can occur rapidly
[20,158,161,170].
Monitoring enteral feedings and verifying tube location
Monitoring patients on enteral feeding is required routine
assessment of gastrointestinal, metabolic, mechanical,
and growth parameters [172]. Tolerance of enteral feeding
is assessed by noting the presence or absence of vomiting,
retching, abdominal distention, and diarrhea. For patients
receiving gastric feedings, checking for residual formula
for every 4 hrs is required to evaluate feeding tolerance or
delayed gastric emptying [173]. During continuous feed-
ing, if a single high gastric residual volume is greater than
1.5 times the hourly feeding of formula infusion, this
indicates a sign of intolerance. Feeding should be
stopped, and clinician should be notified. Gastric residual
should be rechecked every 1-2 hours until the residual
drops below the greater than or equal to 50% of the
hourly rate mark [174]. Decreasing the rate by half for a
few hours, rechecking residuals, and slowly advancing is
recommended to achieve feeding tolerance. Changing the
tube feeding might be beneficial. If this is unsuccessful,
child can be placed in the right lateral decubitus position
and i.v. metaclopromide (Reglan) can be started to
enhance gastric emptying [172,175].
A literature review conducted by Metheny and colleagues
[176] found that there was a confusion as how gastric
residuals should be handled. Fifty percent of the respond-
ents (registered nurses) from a survey (Mateo, 1996, cited
in Metheny et al., 2004) [176] reported discarding the gas-
tric contents and 49% reported re-administering them.
Only one study was located that dealt with outcomes of
discarding or returning gastric residuals to the patients
(Brooker et al., 2000, cited in Metheny et al., 2004) [176].
In this study 35 subjects receiving enteral feedings were
randomized to either a discard group or a return group.
Repeated measures analysis of variance found no signifi-
cant differences between the two groups in the body
weight, serum electrolyte levels, tube clogging, nausea,
and the feeding delays. In the absence of more convincing
evidence, Metheny and colleagues [176] suggest for
returning gastric residuals less than 500 mL to the
patients.
Ensuring correct placement of the feeding tube is also nec-
essary. Although auscultation is the most common
method of confirming placement, it has been found unre-
liable. The best evidence for confirming correct tube
placement is X-ray [177]. Metheny and colleagues
[177,178] provide evidence-based nonradiographic
methods to check the tube location. There are two meth-
ods currently available at bedside to nurses to test tube
placement during continuous feedings include (1)
observing the appearance of fluid aspirated from the tube,
and (2) measuring the fluid's pH. Gastric pH usually falls
in the range of 1 to 5, whereas intestinal or respiratory pH
is usually 7 or higher. If a pH ≤ 6 is a significant indicator
of the gastric placement, whereas a pH >6 is an indicator
of intestinal placement. Metheny and Stewart [178] also
provide additional methods for checking the position of
the tube, such as capnography, spring-gauge pressure
manometer, enzyme tests (pepsin and trypsin), and
bilirubin analysis; however, the most reliable method of
tube placement assessment is the radiograph [172].
Monitoring TPN complications
According to American Gastroenterological Association
(AGA) [77], and American society for parenteral and
enteral nutrition (ASPEN) guidelines [161], TPN should
be infused via single lumen catheter with its tip posi-
tioned in either the superior vena cava or inferior venaBMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
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cava to decrease the risk of infection and trombosis. Tun-
nelled catheters, implantable port, or percutaneously
inserted central catheters (PICCs) should be used at
home. Peripheral infusion of parenteral formulations is
limited to dextrose concentrations of less than 12.5%
[161]. ASPEN suggests that initially, TPN should be
started with low dextrose infusion rate [161]. Starting rate
is usually half of the hourly rate for the first hour, and
then rate is increased to full rate after checking the blood
sugar. Blood glucose should be monitored at least 4 times
a day, and should be <180-200 mg/dl [77]. Glucose intol-
erance is the major adverse effect seen during the initial
infusion period [179]. Urine sugar and acetone or ketone
levels should be less than 2+. ASPEN suggests that dex-
trose infusion rates in infants and neonates should be 10
to 14 mg/kg per minutes[161]. Continuous insulin infu-
sion (0.01-0.1 unit/kg per hour) has been shown to be
safe and effective in managing hyperglycaemia in the
neonate. Glucose concentration should be monitored at
least every 2 hours, aiming for blood glucose concentra-
tion between 100 and 150 mg/dL. In children less than 2
years of age, hypoglycaemia develops rapidly if feedings
are delayed or interrupted. ASPEN recommends that TPN
be tapered over 1 to 2 hours in infants before discontinu-
ation to avoid hypoglycaemia [161]. Some iv medications
need to be administered over 30 to 60 minutes. If the
patient has only one line which TPN is running, the nurse
should communicate with the paediatric pharmacist to
reconstitute the drug with 5% or 10% dextrose if that drug
is incompatible with TPN. This will also prevent
hypoglycaemia if TPN is temporarily interrupted for iv
medication.
Four major categories of complications exist: (1) mechan-
ical or technical; (2) infectious; (3) metabolic; and (4)
nutritional [161]. Mechanical or technical complications
are usually related to catheter placement, such as pneu-
mothorax, hemothorax, cardiac tamponade, or equip-
ment malfunction. Catheter thrombosis is a significant
problem of all central lines. A potential early sign of cath-
eter thrombosis is progressively sluggish or absent blood
return on catheter aspiration. Thrombolytic agents are
effectively used to dissolve thrombi.
Catheter related infections are the most common compli-
cations associated with central line TPN [161]. Localized
infections are, such as erythema, tenderness, induration,
or purulence that occurs at the exit-site or along the tun-
nel. Pocket infections occur only with implantable ports.
Systemic infections, formerly called catheter sepsis or
bacteraemia, are defined as positive culture of the catheter
tip or a positive pathogen isolated from both blood drawn
through the catheter and peripherally. Staphylococcus epi-
dermidis, Staphylococcus aureus, and other skin flora are the
most common pathogens isolated in patients with sys-
temic infections. Enterococcus and enteric flora are the
next most frequently isolated organisms. Catheter-related
infections are treated based on the type of infection and
pathogen [161].
Conclusion
TPN is a life saving alternative nutritional support to
severely malnourished surgical patients. Its use is indi-
cated to prevent the adverse effects of malnutrition in
patients who are unable to tolerate nutrients by oral or
enteral routes. Evidence from a large systematic reviews
involving 82 randomized control clinical trials on both
adult and paediatric population showed that: 1) TPN did
not have a significant impact on survival, 2) TPN did not
affect either the total or infectious complication rates, 3)
TPN had no effect on the duration of hospitalization of
surgical patients [180]. Based on the current evidence,
TPN seems to be safe and a life saving solution.
List of abbreviations used
Short bowel syndrome (SBS)
Total parenteral nutrition (TPN).
Immunoglobulin A (IgA)
Secretory immunoglobulin A (S-IgA),
Gut-associated lymphoid tissue (GALT)
Gastrointestinal (GI)
Mucosa-associated lymphoid tissue (MALT)
Necrotizing enterocolitis (NEC)
Migrating motor complex (MMC),
Histamine2 (H2)
Nitric oxide (NO),
Nitric oxide synthase (NOS
Nonsteroidal anti-inflammatory drugs (NSAIDs)
Tumor necrosis factor (TNF)
Interleukin-1 (IL-1)
Interleukin-6 (IL-6)
Adrenocorticotropic hormone (ACTH)
Antidiuretic hormone (ADH),BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
Page 18 of 22
(page number not for citation purposes)
Free fatty acids (FFA),
Pathogenic microorganism (PPM)
Neutrophil polymorhonuclear (PMN)
Prospective randomized clinical trials (PRCT)
Intensive Care Unit (ICU)
Nasogastric (NG)
Gastrostomy tube (GT)
Nasojejunal (NJ)
Jejunostomy tube (JT)
American Gastroenterological Association (AGA)
American society for parenteral and enteral nutrition
(ASPEN)
Percutaneously inserted central catheters (PICCs)
Competing interests
The author(s) declare that they have no competing
interests.
Acknowledgements
I would like to thank my BMC Nursing reviewers, Dr. Jeejeebhoy and Dr. 
Sigalet for constructively critiquing my paper and giving me the best valuable 
suggestions to improve my research writing. I would like to express my 
deepest respect, appreciation, and thank my admired professors Patricia J. 
Neafsey, RD, PhD, Cheryl Tatano Beck DNSc, CNM, FAAN, and Carol 
Polifroni, RN, EdD, CNAA at the University of Connecticut for editing and 
reading many times my previous draft papers and giving me the most valued 
suggestions. I would also like to thank Wendy Mackey, APRN, MSN, CNS 
at Yale University, Pediatric Surgery for reviewing my previous manu-
scripts; Jan Glover, MLS, AHIP, a Senior Reference Librarian at Yale Univer-
sity Medical Library for giving me an initial crash course in library science 
and electronic biomedical databases. I also would like to thank the library 
staff at the University of Connecticut interlibrary loan department, UConn 
Health Center Medical Library staff, Sasha Singer and Wilhelmina Buckley; 
and Yale University Medical Library staff for their great patience with my 
over due books and their support.
References
1. Kudsk KA: Current aspects of mucosal immunology and its
influence by nutrition. Am J Surg 2002, 183:390-398.
2. Dudrick SJ, Wilmore DW, Vars HM, Rhoads JE: Long-term total
parenteral nutrition with growth, development, and positive
nitrogen balance. Surgery 1968, 64:134-142.
3. Buchman AL, Moukarzel AA, Bhuta S, Belle M, Ament ME, Eckhert
CD, Hollander D, Gornbein J, Kopple JD, Vijayaroghavan SR:
Parenteral nutrition is associated with intestinal morpho-
logic and functional changes in humans. JPEN J Parenter Enteral
Nutr 1995, 19:453-460.
4. Falcone RA, Warner BW: Pediatric parenteral nutrition. In Clin-
ical nutrition : parenteral nutrition 3rd edition. Edited by: Rombeau JL
and Rolandelli R. Philadelphia, W.B. Saunders; 2001:476-496. 
5. Chaet MS, Farrell MK, Ziegler MM, Warner BW: Intensive nutri-
tional support and remedial surgical intervention for
extreme short bowel syndrome. J Pediatr Gastroenterol Nutr 1994,
19:295-298.
6. Suita S, Masumoto K, Yamanouchi T, Nagano M, Nakamura M: Com-
plications in neonates with short bowel syndrome and long-
term parenteral nutrition.  JPEN J Parenter Enteral Nutr 1999,
23:S106-9.
7. Okada Y, Klein NJ, van-Saene HK, Webb G, Holzel H, Pierro A: Bac-
tericidal activity against coagulase-negative staphylococci is
impaired in infants receiving long-term parenteral nutrition.
Ann Surg 2000, 231:276-281.
8. Alverdy JC, Aoys E, Moss GS: Total parenteral nutrition pro-
motes bacterial translocation from the gut.  Surgery 1988,
104:185-190.
9. Sakamoto K, Hirose H, Onizuka A, Hayashi M, Futamura N, Kawa-
mura Y, Ezaki T: Quantitative study of changes in intestinal
morphology and mucus gel on total parenteral nutrition in
rats. J Surg Res 2000, 94:99-106.
10. McAndrew HF, Lloyd DA, Rintala R, van-Saene HK: The effects of
intravenous epidermal growth factor on bacterial transloca-
tion and central venous catheter infection in the rat total
parenteral nutrition model. Pediatr Surg Int 2000, 16:169-173.
11. Ganessunker D, Gaskins HR, Zuckermann FA, Donovan SM: Total
parenteral nutrition alters molecular and cellular indices of
intestinal inflammation in neonatal piglets.  JPEN J Parenter
Enteral Nutr 1999, 23:337-344.
12. Alverdy J, Chi HS, Sheldon GF: The effect of parenteral nutrition
on gastrointestinal immunity. The importance of enteral
stimulation. Ann Surg 1985, 202:681-684.
13. King BK, Li J, Kudsk KA: A temporal study of TPN-induced
changes in gut-associated lymphoid tissue and mucosal
immunity. Arch Surg 1997, 132:1303-1309.
14. Li J, Kudsk KA, Gocinski B, Dent D, Glezer J, Langkamp-Henken B:
Effects of parenteral and enteral nutrition on gut-associated
lymphoid tissue. J Trauma 1995, 39:44-51; discussion 51-2.
15. Wang HT, Sax HC: Total parenteral nutrition: effects on the
small intestine. In Clinical nutrition : parenteral nutrition 3rd edition.
Edited by: Rombeau JL and Rolandelli R. Philadelphia, W.B. Saunders;
2001:353-363. 
16. Neu J, Weiss MD: Necrotizing enterocolitis: pathophysiology
and prevention. JPEN J Parenter Enteral Nutr 1999, 23:S13-7.
17. Vanderhoof JA: Short-bowel syndrome and intestinal adapta-
tion. In Pediatric gastrointestinal disease : pathophysiology, diagnosis, man-
agement 3rd edition. Edited by: Walker WA, Durie PR, Hamilton JR
and Walker-Smith JA. Ontario ; New York, B.C. Decker;
2000:583-602. 
18. Shou J, Lappin J, Minnard EA, Daly JM: Total parenteral nutrition,
bacterial translocation, and host immune function. Am J Surg
1994, 167:145-150.
19. Piena-Spoel M, Sharman-Koendjbiharie M, Yamanouchi T, Tibboel D:
"Gut-feeling" or evidence-based approaches in the evalua-
tion and treatment of human short-bowel syndrome. Pediatr
Surg Int 2000, 16:155-164.
20. Serrano MS, Schmidt-Sommerfeld E: Nutrition support of infants
with short bowel syndrome. Nutrition 2002, 18:966-970.
21. Murphy MS: The management of short bowel syndrome. Cur-
rent Paediatrics 2001, 11:264-268.
22. Touloukian RJ, Smith GJW: Normal intestinal length in preterm
infants. J of Pediatr Surg 1983, 18: 720-723.
23. Jeejeebhoy KN: Short bowel syndrome: a nutritional and med-
ical approach. Cmaj 2002, 166:1297-1302.
24. Huether SE, McCance KL: Understanding pathophysiology. 2nd
edition. St. Louis, Mosby; 2000:917-941. 
25. Fukuchi S, Bankhead R, Rolandelli RH: Parenteral nutrition in
short bowel syndrome. In Clinical nutrition : parenteral nutrition 3rd
edition. Edited by: Rombeau JL and Rolandelli R. Philadelphia, W.B.
Saunders; 2001:282-303. 
26. Sanderson IR, Walker WA: Mucosal barrier: an overwiew. In
Mucosal immunology 2nd edition. Edited by: Ogra PL, Mestecky J,
Lamm M, Strober W, Bienenstock J and McGhee JR. San Diego, Aca-
demic Press; 1999:5-17. 
27. Sherwood L: Fundamentals of physiology: A human perspec-
tive. 2nd edition. 610 Opperman Drive, St. Paul, MN 55164-0526,
West Publishing Co; 1995:450. BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
Page 19 of 22
(page number not for citation purposes)
28. Lichtman SN: Bacterial overgrowth. In Pediatric gastrointestinal dis-
ease : pathophysiology, diagnosis, management 3rd edition. Edited by:
Walker WA, Durie PR, Hamilton JR, Walker-Smith JA and Watkins
JB. Ontario ; New York, B.C. Decker; 2000:569-582. 
29. Hodin RA, Matthews JB: Small Intestine. In Surgery : basic science
and clinical evidence Edited by: Norton JA. New York, Springer;
2001:617-646. 
30. Berne RM, Levy MN: Physiology. 4th edition. 11830 Westline Drive,
St. Louis, Missouri 63146, Mosby-Year Book, Inc; 1998:589. 
31. Martini F: Fundamentals of anatomy and physiology. 4th edi-
tion. Upper Saddle River, N.J., Prentice Hall; 1998:xxx, 985 , [79]. 
32. Kato T, Owen RL: Structure and function of intestinal mucosal
epithelium. In Mucosal immunology 2nd edition. Edited by: Ogra PL.
San Diego, Academic Press; 1999:115-132. 
33. Janson DD: Enteral nutrition. In Pharmacotherapy : a pathophysio-
logic approach 4th edition. Edited by: DiPiro JT, Talbert RL, Yee GC,
Matzke GR, Waells BG and Posey ML. Stamford, Conn., Appleton &
Lange; 1999:2268-2292. 
34. Nemanich M, Behrns KE, Sarr MG: Motilin, Erythromycin, and
the Gastric Migrating Motor Complex - Site of Action. Journal
of Gastrointestinal Motility 1993, 5:253-263.
35. Giannella RA, Broitman SA, Zamcheck N: Influence of gastric acid-
ity on bacterial and parasitic enteric infections. A
perspective. Ann Intern Med 1973, 78:271-276.
36. Snepar R, Poporad GA, Romano JM, Kobasa WD, Kaye D: Effect of
cimetidine and antacid on gastric microbial flora. Infect Immun
1982, 36:518-524.
37. Thomson AB, Keelan M, Thiesen A, Clandinin MT, Ropeleski M, Wild
GE: Small bowel review: normal physiology part 2. Dig Dis Sci
2001, 46:2588-2607.
38. Sasaki K, Park JO, Bain A, Reilly KJ, Adamson WT, Koide S, Zhang W,
Rombeau JL: Glutamine protects function and improves pres-
ervation of small bowel segments. Journal of Surgical Research
1997,  73:90-94.
39. Sigalet DL, Mackenzie SL, Hameed SM: Enteral nutrition and
mucosal immunity: implications for feeding strategies in sur-
gery and trauma. Can J Surg 2004, 47:109-116.
40. Thomson AB, Jarocka-Cyrta E, Faria J, Wild GE: Small bowel
review--Part II. Can J Gastroenterol 1997, 11:159-165.
41. Thomson AB, Jarocka-Cyrta E, Faria J, Wild GE: Small bowel
review--Part I. Can J Gastroenterol 1997, 11:49-56.
42. Thomson AB, Keelan M, Thiesen A, Clandinin MT, Ropeleski MJ, Wild
G:  Small bowel review: part I.  Can J Gastroenterol 2000,
14:791-816.
43. Nadler EP, Ford HR: Regulation of bacterial translocation by
nitric oxide. Pediatr Surg Int 2000, 16:165-168.
44. Kanwar S, Wallace JL, Befus D, Kubes P: Nitric oxide synthesis
inhibition increases epithelial permeability via mast cells. Am
J Physiol 1994, 266:G222-9.
45. Thomson AB, Drozdowski L, Iordache C, Thomson BK, Vermeire S,
Clandinin MT, Wild G: Small bowel review: Normal physiology,
part 2. Dig Dis Sci 2003, 48:1565-1581.
46. Mayer L: Mucosal immunity and gastrointestinal antigen
processing. Journal of Pediatric Gastro and Nutrition 2000,  30:(Supple-
ment content) S4-S12.
47. SpÃ¤th PJ: Structure and function of immunoglobulins. Sepsis
1999, 3:197-218.
48. Wren SM, Simmons RL, Ildstad ST: Bacterial translocation: The
gut as a mucosal barrier. In infections and immunologic disorders in
pediatric surgery Edited by: Fonkalsrud EW and Krummel TM. Philadel-
phia, W.B. Saunders; 1993:53-61. 
49. Douglas RG, Shaw JH: Metabolic response to sepsis and trauma.
Br J Surg 1989, 76:115-122.
50. Corwin EJ: Understanding cytokines. Part I: Physiology and
mechanism of action. Biological Research for Nursing 2000, 2:30-40.
51. Okada Y, Papp E, Klein NJ, Pierro A: Total parenteral nutrition
directly impairs cytokine production after bacterial
challenge. J Pediatr Surg 1999, 34:277-280.
52. Benjamini E, Coico R, Sunshine GH: Immunology : a short course.
4th edition. New York, Wiley-Liss; 2000:xix, 498. 
53. Montori VM, Bistrian BR, McMahon MM: Hyperglycemia in
acutely ill patients. Jama 2002, 288:2167-2169.
54. Andersen SK, Gjedsted J, Christiansen C, Tonnesen E: The roles of
insulin and hyperglycemia in sepsis pathogenesis. J Leukoc Biol
2004, 75:413-421.
55. Wilschanski M, Shamir R: Short bowel syndrome. In Clinical pediat-
ric gastroenterology Edited by: Altschuler S and Liacouras CA. Philadel-
phia, W.B. Saunders; 1998:285-290. 
56. Sigalet DL: Short bowel syndrome in infants and children: an
overview. Semin Pediatr Surg 2001, 10:49-55.
57. Heine RG, Bines JE: New approaches to parenteral nutrition in
infants and children. J Paediatr Child Health 2002, 38:433-437.
58. Pierro A, van-Saene HK, Jones MO, Brown D, Nunn AJ, Lloyd DA:
Clinical impact of abnormal gut flora in infants receiving
parenteral nutrition. Ann Surg 1998, 227:547-552.
59. Vanderhoof JA, Young RJ: Chronic complications of the short
bowel syndrome in children. In Uptodate Edited by: Rose BD.
Wellesley, MA, Uptodate inc.; 2003. 
60. Pierro A, van Saene HK, Donnell SC, Hughes J, Ewan C, Nunn AJ,
Lloyd DA: Microbial translocation in neonates and infants
receiving long-term parenteral nutrition.  Arch Surg 1996,
131:176-179.
61. Woodcock NP, Robertson J, Morgan DR, Gregg KL, Mitchell CJ, Mac-
Fie J: Bacterial translocation and immunohistochemical
measurement of gut immune function.  J Clin Pathol 2001,
54:619-623.
62. MacFie J, O'Boyle C, Mitchell CJ, Buckley PM, Johnstone D, Sudworth
P: Gut origin of sepsis: a prospective study investigating asso-
ciations between bacterial translocation, gastric microflora,
and septic morbidity. Gut 1999, 45:223-228.
63. Saez-Llorens X, McCracken GHJ: Sepsis syndrome and septic
shock in pediatrics: current concepts of terminology, patho-
physiology, and management. J Pediatr 1993, 123:497-508.
64. Johnston JD, Harvey CJ, Menzies IS, Treacher DF: Gastrointestinal
permeability and absorptive capacity in sepsis. Crit Care Med
1996, 24:1144-1149.
65. Khaodhiar L, Bistrian: Avoidanca and management of complica-
tions of parenteral nutrition.  Nutrition in Clinical Care 1999,
2:239-249.
66. Lenders CM, Lo C: Pediatric parenteral nutrition. Nutrition in
Clinical Care 1999, 2:219-229.
67. Okada Y, Klein NJ, Pierro A: Neutrophil dysfunction: The cellu-
lar mechanism of impaired immunity during total parenteral
nutrition in infancy. J Pediatr Surg 1999, 34:242-245.
68. Coppola CP, Dudrick SJ: Total parenteral nutrition and
infections. Curr Surg 2001, 58:23-28.
69. Nordenstrom J, Jarstrand C, Wiernik A: Decreased chemotactic
and random migration of leukocytes during Intralipid
infusion. Am J Clin Nutr 1979, 32:2416-2422.
70. Freeman J, Goldmann DA, Smith NE, Sidebottom DG, Epstein MF,
Platt R: Association of intravenous lipid emulsion and coagu-
lase-negative staphylococcal bacteremia in neonatal inten-
sive care units. N Engl J Med 1990, 323:301-308.
71. Fischer GW, Hunter KW, Wilson SR, Mease AD: Diminished bac-
terial defences with intralipid. Lancet 1980, 2:819-820.
72. Wanten G, van Emst-De Vries S, Naber T, Willems P: Nutritional
lipid emulsions modulate cellular signaling and activation of
human neutrophils. J Lipid Res 2001, 42:428-436.
73. Monson JR, Ramsden CW, MacFie J, Brennan TG, Guillou PJ: Immu-
norestorative effect of lipid emulsions during total
parenteral nutrition. Br J Surg 1986, 73:843-846.
74. Sedman PC, Somers SS, Ramsden CW, Brennan TG, Guillou PJ:
Effects of different lipid emulsions on lymphocyte function
during total parenteral nutrition. Br J Surg 1991, 78:1396-1399.
75. Ota DM, Jessup JM, Babcock GF, Kirschbaum L, Mountain CF,
McMurtrey MJ, Copeland EM: Immune function during intrave-
nous administration of a soybean oil emulsion. JPEN J Parenter
Enteral Nutr 1985, 9:23-27.
76. Palmblad J, Brostrom O, Lahnborg G, Uden AM, Venizelos N: Neu-
trophil functions during total parenteral nutrition and Intral-
ipid infusion. Am J Clin Nutr 1982, 35:1430-1436.
77. Buchman AL, Scolapio J, Fryer J: AGA technical review on short
bowel syndrome and intestinal transplantation. Gastroenterol-
ogy 2003, 124:1111-1134.
78. Cook DJ, Sackett DL, Spitzer WO: Methodologic guidelines for
systematic reviews of randomized control trials in health
care from the Potsdam Consultation on Meta-Analysis. J Clin
Epidemiol 1995, 48:167-171.
79. Cooper HM: Integrating research : a guide for literature
reviews. In Applied social research methods series v 2 2nd edition. New-
bury Park, Calif., Sage Publications; 1989:157. BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
Page 20 of 22
(page number not for citation purposes)
80. NHS Centre for Reviews and Dissemination: Undertaking system-
atic reviews of research on effectiveness: CRDâ€™s guid-
ance for those carrying out or commissioning reviews. Edited
by: Khalid S Khan GRJGAJSJ and Kleijnen . York: CRD report number
4 (2nd edition)., University of York; 2001. 
81. Cook DJ, Mulrow CD, Haynes RB: Systematic reviews: synthesis
of best evidence for clinical decisions. Ann Intern Med 1997,
126:376-380.
82. Light RJ, Pillemer DB: Summing up : the science of reviewing
research. Cambridge, Mass., Harvard University Press; 1984:xiii,
191. 
83. Imperiale TF: Meta-analysis: when and how.  Hepatology 1999,
29:26S-31S.
84. Bland CJ, Meurer LN, Maldonado G: A systematic approach to
conducting a non-statistical meta-analysis of research
literature. Acad Med 1995, 70:642-653.
85. Jadad AR, Moher D, Klassen TP: Guides for reading and inter-
preting systematic reviews  II. How did the authors find the
studies and assess their quality? Archives of Pediatrics and Adoles-
cent Medicine 1998, 152:812-817.
86. Meade MO, Richardson WS: Selecting and appraising studies for
a systematic review. Ann Intern Med 1997, 127:531-537.
87. Mulrow CD: The medical review article: state of the science.
Ann Intern Med 1987, 106:485-488.
88. Mulrow CD, Cook D: Systematic reviews : synthesis of best evi-
dence for health care decisions. Philadelphia, Pa., American Col-
lege of Physicians; 1998:x, 117. 
89. Oxman AD, Cook DJ, Guyatt GH: Users' guides to the medical
literature. VI. How to use an overview. Evidence-Based Med-
icine Working Group. Jama 1994, 272:1367-1371.
90. Dahlstrom KAB: Long Term Parenteral Nutrition in Children:
A Nutritional, Metabolic and Immunological Study. Repro-
print Ab, Box 21085, S-100 31 Stockholm, Sweden, Karolinska Insti-
tutet (Sweden); 1988. 
91. Smith L, Deeks J: Should case-control studies be included in
systematic reviews of the effects of healthcare interventions?
Cochrane 2001, 1:op036.
92. Khan KS: Systematic reviews to support evidence-based med-
icine : how to review and apply findings of healthcare
research. London, Royal Society of Medicine Press; 2003:xi, 136. 
93. Rossi TM, Lee PC, Young C, Tjota A: Small intestinal mucosa
changes, including epithelial cell proliferative activity, of chil-
dren receiving total parenteral nutrition (TPN). Dig Dis Sci
1993, 38:1608-1613.
94. Weber TR: Enteral feeding increases sepsis in infants with
short bowel syndrome. J Pediatr Surg 1995, 30:1086-8; discussion
1088-9.
95. Bines J, Francis D, Hill D: Reducing parenteral requirement in
children with short bowel syndrome: impact of an amino
acid-based complete infant formula. J Pediatr Gastroenterol Nutr
1998, 26:123-128.
96. Andorsky DJ, Lund DP, Lillehei CW, Jaksic T, Dicanzio J, Richardson
DS, Collier SB, Lo C, Duggan C: Nutritional and other postoper-
ative management of neonates with short bowel syndrome
correlates with clinical outcomes. J Pediatr 2001, 139:27-33.
97. Sondheimer JM, Cadnapaphornchai M, Sontag M, Zerbe GO: Pre-
dicting the duration of dependence on parenteral nutrition
after neonatal intestinal resection. J Pediatr 1998, 132:80-84.
98. Kaufman SS, Loseke CA, Lupo JV, Young RJ, Murray ND, Pinch LW,
Vanderhoof JA: Influence of bacterial overgrowth and intesti-
nal inflammation on duration of parenteral nutrition in chil-
dren with short bowel syndrome. J Pediatr 1997, 131:356-361.
99. Beck CT: Meta-analysis: overview and application to clinical
nursing practice. J Obstet Gynecol Neonatal Nurs 1995, 24:131-135.
100. Mulrow C, Langhorne P, Grimshaw J: Integrating heterogeneous
pieces of evidence in systematic reviews. Ann Intern Med 1997,
127:989-995.
101. Cooper HM: Synthesizing research : a guide for literature
reviews. In Applied social research methods series ; v 2 3rd edition.
Thousand Oaks, Calif., Sage Publications; 1998:xii, 201. 
102. Sedman PC, MacFie J, Palmer MD, Mitchell CJ, Sagar PM: Preopera-
tive total parenteral nutrition is not associated with mucosal
atrophy or bacterial translocation in humans. Br J Surg 1995,
82:1663-1667.
103. Guedon C, Schmitz J, Lerebours E, Metayer J, Audran E, Hemet J,
Colin R: Decreased brush border hydrolase activities without
gross morphologic changes in human intestinal mucosa after
prolonged total parenteral nutrition of adults. Gastroenterology
1986, 90:373-378.
104. Pironi L, Paganelli GM, Miglioli M, Biasco G, Santucci R, Ruggeri E, Di-
Febo G, Barbara L: Morphologic and cytoproliferative patterns
of duodenal mucosa in two patients after long-term total
parenteral nutrition: changes with oral refeeding and rela-
tion to intestinal resection. JPEN J Parenter Enteral Nutr 1994,
18:351-354.
105. Groos S, Hunefeld G, Luciano L: Parenteral versus enteral nutri-
tion: morphological changes in human adult intestinal
mucosa. J Submicrosc Cytol Pathol 1996, 28:61-74.
106. Lipman TO: Grains or veins: is enteral nutrition really better
than parenteral nutrition? A look at the evidence.  JPEN J
Parenter Enteral Nutr 1998, 22:167-182.
107. Lipman TO: Bacterial translocation and enteral nutrition in
humans: an outsider looks in. JPEN J Parenter Enteral Nutr 1995,
19:156-165.
108. El Kaissouni J, Bene MC, Thionnois S, Monin P, Vidailhet M, Faure GC:
Maturation of B cells in the lamina propria of human gut and
bronchi in the first months of human life. Dev Immunol 1998,
5:153-159.
109. Buchman AL, Mestecky J, Moukarzel A, Ament ME: Intestinal
immune function is unaffected by parenteral nutrition in
man. J Am Coll Nutr 1995, 14:656-661.
110. Hennessey PJ, Black CT, Andrassy RJ: Nonenzymatic glycosyla-
tion of immunoglobulin G impairs complement fixation. Jpen:
Journal of Parenteral & Enteral Nutrition 1991, 15:60-64.
111. Gore DC, Chinkes D, Heggers J, Herndon DN, Wolf SE, Desai M:
Association of hyperglycemia with increased mortality after
severe burn injury. J Trauma 2001, 51:540-544.
112. Rassias AJ, Givan AL, Marrin CA, Whalen K, Pahl J, Yeager MP: Insu-
lin increases neutrophil count and phagocytic capacity after
cardiac surgery. Anesth Analg 2002, 94:1113-9, table of contents.
113. Rassias AJ, Marrin CA, Arruda J, Whalen PK, Beach M, Yeager MP:
Insulin infusion improves neutrophil function in diabetic car-
diac surgery patients. Anesth Analg 1999, 88:1011-1016.
114. Jeejeebhoy KN: Total parenteral nutrition: potion or poison?
Am J Clin Nutr 2001, 74:160-163.
115. Campbell KB, Braithwaite SS: Hospital management of
hyperglycemia. Clinical Diabetes 2004, 22:81-88.
116. Rosmarin DK, Wardlaw GM, Mirtallo J: Hyperglycemia associ-
ated with high, continuous infusion rates of total parenteral
nutrition dextrose. Nutr Clin Pract 1996, 11:151-156.
117. McCowen KC, Malhotra A, Bistrian BR: Stress-induced
hyperglycemia. Crit Care Clin 2001, 17:107-124.
118. van-den-Berghe G, Wouters P, Weekers F, Verwaest C, Bruyninckx
F, Schetz M, Vlasselaers D, Ferdinande P, Lauwers P, Bouillon R:
Intensive insulin therapy in the critically ill patients. N Engl J
Med 2001, 345:1359-1367.
119. Malmberg K, Ryden L, Efendic S, Herlitz J, Nicol P, Waldenstrom A,
Wedel H, Welin L: Randomized trial of insulin-glucose infusion
followed by subcutaneous insulin treatment in diabetic
patients with acute myocardial infarction (DIGAMI study):
effects on mortality at 1 year. J Am Coll Cardiol 1995, 26:57-65.
120. Mizock BA: Alterations in carbohydrate metabolism during
stress: a review of the literature. Am J Med 1995, 98:75-84.
121. Kudsk KA, Li J, Renegar KB: Loss of upper respiratory tract
immunity with parenteral feeding. Ann Surg 1996, 223:629-35;
discussion 635-8.
122. Pancorbo-Hidalgo PL, Garcia-Fernandez FP, Ramirez-Perez C: Com-
plications associated with enteral nutrition by nasogastric
tube in an internal medicine unit. J Clin Nurs 2001, 10:482-490.
123. Mentec H, Dupont H, Bocchetti M, Cani P, Ponche F, Bleichner G:
Upper digestive intolerance during enteral nutrition in criti-
cally ill patients: frequency, risk factors, and complications.
Crit Care Med 2001, 29:1955-1961.
124. Marik PE, Zaloga GP: Early enteral nutrition in acutely ill
patients: a systematic review. Crit Care Med 2001, 29:2264-2270.
125. Klein S, Kinney J, Jeejeebhoy K, Alpers D, Hellerstein M, Murray M,
Twomey P: Nutrition support in clinical practice: review of
published data and recommendations for future research
directions. Summary of a conference sponsored by the
National Institutes of Health, American Society for
Parenteral and Enteral Nutrition, and American Society for
Clinical Nutrition. Am J Clin Nutr 1997, 66:683-706.BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
Page 21 of 22
(page number not for citation purposes)
126. Daly JM, Lieberman MD, Goldfine J, Shou J, Weintraub F, Rosato EF,
Lavin P: Enteral nutrition with supplemental arginine, RNA,
and omega-3 fatty acids in patients after operation: immuno-
logic, metabolic, and clinical outcome. Surgery 1992, 112:56-67.
127. Braga M, Gianotti L, Vignali A, Cestari A, Bisagni P, Di-Carlo V: Arti-
ficial nutrition after major abdominal surgery: impact of
route of administration and composition of the diet. Crit Care
Med 1998, 26:24-30.
128. MacFie J: Enteral versus parenteral nutrition: the significance
of bacterial translocation and gut-barrier function. Nutrition
2000, 16:606-611.
129. McClave SA, Lowen CC, Snider HL: Immunonutrition and
enteral hyperalimentation of critically ill patients. Dig Dis Sci
1992, 37:1153-1161.
130. Koretz RL: Immunonutrition: fact, fantasy, and future. Curr
Gastroenterol Rep 2002, 4:332-337.
131. O'Dwyer ST, Smith RJ, Hwang TL, Wilmore DW: Maintenance of
small bowel mucosa with glutamine-enriched parenteral
nutrition. JPEN J Parenter Enteral Nutr 1989, 13:579-585.
132. Jacobs DO, Evans DA, Mealy K, O'Dwyer ST, Smith RJ, Wilmore DW:
Combined effects of glutamine and epidermal growth factor
on the rat intestine. Surgery 1988, 104:358-364.
133. Alverdy JA, Aoys E, Weiss-Carrington P, Burke DA: The effect of
glutamine-enriched TPN on gut immune cellularity. J Surg Res
1992, 52:34-38.
134. Burke DJ, Alverdy JC, Aoys E, Moss GS: Glutamine-supplemented
total parenteral nutrition improves gut immune function.
Arch Surg 1989, 124:1396-1399.
135. Darmaun D, Messing B, Just B, Rongier M, Desjeux JF: Glutamine
metabolism after small intestinal resection in humans. Metab-
olism 1991, 40:42-44.
136. Hankard R, Goulet O, Ricour C, Rongier M, Colomb V, Darmaun D:
Glutamine metabolism in children with short-bowel syn-
drome: a stable isotope study. Pediatr Res 1994, 36:202-206.
137. Alexander JW: Immunoenhancement via enteral nutrition.
Arch Surg 1993, 128:1242-1245.
138. Li L, Irving M: The effectiveness of growth hormone, glutamine
and a low-fat diet containing high-carbohydrate on the
enhancement of the function of remnant intestine among
patients with short bowel syndrome: a review of published
trials. Clin Nutr 2001, 20:199-204.
139. Byrne TA, Morrissey TB, Nattakom TV, Ziegler TR, Wilmore DW:
Growth hormone, glutamine, and a modified diet enhance
nutrient absorption in patients with severe short bowel
syndrome. JPEN J Parenter Enteral Nutr 1995, 19:296-302.
140. Byrne TA, Persinger RL, Young LS, Ziegler TR, Wilmore DW: A new
treatment for patients with short-bowel syndrome. Growth
hormone, glutamine, and a modified diet.  Ann Surg 1995,
222:243-54; discussion 254-5.
141. Seguy D, Vahedi K, Kapel N, Souberbielle JC, Messing B: Low-dose
growth hormone in adult home parenteral nutrition-
dependent short bowel syndrome patients: a positive study.
Gastroenterology 2003, 124:293-302.
142. Scolapio JS: Effect of growth hormone, glutamine, and diet on
body composition in short bowel syndrome: a randomized,
controlled study. JPEN J Parenter Enteral Nutr 1999, 23:309-12; dis-
cussion 312-3.
143. Jeppesen PB, Szkudlarek J, Hoy CE, Mortensen PB: Effect of high-
dose growth hormone and glutamine on body composition,
urine creatinine excretion, fatty acid absorption, and essen-
tial fatty acids status in short bowel patients: a randomized,
double-blind, crossover, placebo-controlled study.  Scand J
Gastroenterol 2001, 36:48-54.
144. Beaugerie L, Carbonnel F, Hecketsweiler B, Dechelotte P, Gendre JP,
Cosnes J: Effects of an isotonic oral rehydration solution,
enriched with glutamine, on fluid and sodium absorption in
patients with a short-bowel.  Aliment Pharmacol Ther 1997,
11:741-746.
145. Ellegard L, Bosaeus I, Nordgren S, Bengtsson BA: Low-dose recom-
binant human growth hormone increases body weight and
lean body mass in patients with short bowel syndrome. Ann
Surg 1997, 225:88-96.
146. Cukier C, Waitzberg DL, Borges VC, Silva ML, Gama-Rodrigues J,
Pinotti HW: Clinical use of growth hormone and glutamine in
short bowel syndrome. Rev Hosp Clin Fac Med Sao Paulo 1999,
54:29-34.
147. Scolapio JS, McGreevy K, Tennyson GS, Burnett OL: Effect of
glutamine in short-bowel syndrome. Clin Nutr 2001, 20:319-323.
148. Mascarenhas MR, Kerner JA, Stalling VA: Parenteral and enteral
nutrition. In Pediatric gastrointestinal disease : pathophysiology, diagno-
sis, management 3rd edition. Edited by: Walker WA, Durie PR, Ham-
ilton JR and Walker-Smith JA. Ontario ; New York, B.C. Decker;
2000:1705-1752. 
149. Duggan C, Stark AR, Auestad N, Collier S, Fulhan J, Gura K, Utter S,
Teixeira-Pinto A, Donovan K, Lund D: Glutamine supplementa-
tion in infants with gastrointestinal disease: a randomized,
placebo-controlled pilot trial. Nutrition 2004, 20:752-756.
150. Barbosa E, Moreira EA, Goes JE, Faintuch J: Pilot study with a
glutamine-supplemented enteral formula in critically ill
infants. Rev Hosp Clin Fac Med Sao Paulo 1999, 54:21-24.
151. Scolapio JS, Camilleri M, Fleming CR, Oenning LV, Burton DD, Sebo
TJ, Batts KP, Kelly DG: Effect of growth hormone, glutamine,
and diet on adaptation in short-bowel syndrome: a rand-
omized, controlled study. Gastroenterology 1997, 113:1074-1081.
152. Szkudlarek J, Jeppesen PB, Mortensen PB: Effect of high dose
growth hormone with glutamine and no change in diet on
intestinal absorption in short bowel patients: a randomised,
double blind, crossover, placebo controlled study. Gut 2000,
47:199-205.
153. Garcia-de-Lorenzo A, Zarazaga A, Garcia-Luna PP, Gonzalez-Huix F,
Lopez-Martinez J, Mijan A, Quecedo L, Casimiro C, Usan L, del-Llano
J:  Clinical evidence for enteral nutritional support with
glutamine: a systematic review. Nutrition 2003, 19:805-811.
154. Beale RJ, Bryg DJ, Bihari DJ: Immunonutrition in the critically ill:
a systematic review of clinical outcome. Crit Care Med 1999,
27:2799-2805.
155. Heys SD, Walker LG, Smith I, Eremin O: Enteral nutritional sup-
plementation with key nutrients in patients with critical ill-
ness and cancer: a meta-analysis of randomized controlled
clinical trials. Ann Surg 1999, 229:467-477.
156. Kudsk KA, Minard G, Croce MA, Brown RO, Lowrey TS, Pritchard
FE, Dickerson RN, Fabian TC: A randomized trial of isonitroge-
nous enteral diets after severe trauma. An immune-enhanc-
ing diet reduces septic complications.  Ann Surg 1996,
224:531-40; discussion 540-3.
157. Booth IW, Lander AD: Short bowel syndrome.  Baillieres Clin
Gastroenterol 1998, 12:739-773.
158. Vanderhoof JA, Young RJ: Management of the short bowel syn-
drome in children. In Uptodate Edited by: Rose BD. Wellesley, MA,
Uptodate inc.; 2004. 
159. Davis AM, Stanko-Kline R: Pediatrics. In Contemporary nutrition sup-
port practice : a clinical guide 2nd edition. Edited by: Matarese LE and
Gottschlich MM. Philadelphia, Saunders; 2003:357-375. 
160. Hutson J: The compromised gut: what do we really know and
what is clinically relevant? Pediatr Surg Int 2000, 16:153-154.
161. ASPEN-Board-of-Directors-and-the-Clinical-Guidelines-Task-Force:
Guidelines for the use of parenteral and enteral nutrition in
adult and pediatric patients. JPEN J Parenter Enteral Nutr 2002,
26:1SA-138SA.
162. Vanderhoof JA, Langnas AN: Short-bowel syndrome in children
and adults. Gastroenterology 1997, 113:1767-1778.
163. Behrman RE, Kliegman R, Jenson HB: Nelson textbook of pediat-
rics. 16:1162 [http://www.med.yale.edu/medmenu/
info_mdcbooks.html].
164. de Boissieu D, Chaussain M, Badoual J, Raymond J, Dupont C: Small-
bowel bacterial overgrowth in children with chronic
diarrhea, abdominal pain, or both. J Pediatr 1996, 128:203-207.
165. Gilbert-Barness E, Barness LA: Clinical use of pediatric diagnos-
tic tests. Philadelphia, PA, Lippincott Williams & Wilkins;
2003:273-302. 
166. Dellert SF, Nowicki MJ, Farrell MK, Delente J, Heubi JE: The 13C-
xylose breath test for the diagnosis of small bowel bacterial
overgrowth in children.  J Pediatr Gastroenterol Nutr 1997,
25:153-158.
167. Galeano NF, Lepage G, Leroy C, Belli D, Levy E, Roy CC: Compar-
ison of two special infant formulas designed for the treat-
ment of protracted diarrhea. J Pediatr Gastroenterol Nutr 1988,
7:76-83.
168. Parker P, Stroop S, Greene H: A controlled comparison of con-
tinuous versus intermittent feeding in the treatment of
infants with intestinal disease [Abstract].  J Pediatr 1981,
99:360-364.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Nursing 2005, 4:2 http://www.biomedcentral.com/1472-6955/4/2
Page 22 of 22
(page number not for citation purposes)
169. Vanderhoof JA, Young RJ: Enteral nutrition in short bowel
syndrome. Semin Pediatr Surg 2001, 10:65-71.
170. Vanderhoof JA, Young C: Short bowel syndrome. In Pediatric gas-
troenterology and nutrition in clinical practice Edited by: CH Lifschitz.
New York: Marcel Dekker; 2002:701-723. 
171. Alkalay AL, Fleisher DR, Pomerance JJ, Rosenthal P: Management of
premature infants with extensive bowel resection with high
volume enteral infusates [Abstract].  Isr J Med Sci 1995,
31:298-302.
172. Irving SY, Simone SD, Hicks FW, Verger JT: Nutrition for the crit-
ically ill child: enteral and parenteral support. Aacn Clin Issues
Adv Pract Acute Crit Care 2000, 11:541-58, 637-8.
173. Thomas S: Gastrointestinal complications: diarrhea and high
gastric residual. In Enteral nutrition: Chapman & Hall series in clinical
nutrition Edited by: Borlase BC. New York, Chapman & Hall;
1994:188-192. 
174. Edwards SJ, Metheny NA: Measurement of gastric residual vol-
ume: state of the science. Medsurg Nurs 2000, 9:125-128.
175. Davis A: Indications and techniques for enteral feeds. In Pediat-
ric enteral nutrition: Chapman & Hall series in clinical nutrition Edited by:
Baker S, Baker RD and Davis A. New York, NY, Chapman & Hall;
1994:67-94. 
176. Metheny NA, Schallom ME, Edwards SJ: Effect of gastrointestinal
motility and feeding tube site on aspiration risk in critically
ill patients: a review. Heart Lung 2004, 33:131-145.
177. Metheny NA, Titler MG: Assessing placement of feeding tubes.
Am J Nurs 2001, 101:36-46.
178. Metheny NA, Stewart BJ, Wallace M: Testing feeding tube place-
ment during continuous tube feedings.  Appl Nurs Res 2002,
15:254-258.
179. Gomella LG, Haist SA, Billeter M: Clinician's pocket reference.
8th edition. Stamford, CT, Appleton & Lange -Simon & Shuster;
1997:698. 
180. American Gastroenterological Association: American Gastroen-
terological Association medical position statement:
parenteral nutrition. Gastroenterology 2001, 121:966-1001.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1472-6955/4/2/prepub